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ABSTRACT: Free fatty acid receptor 2 (FFA2/GPR43) is a
receptor for short-chain fatty acids reported to be involved in
regulation of metabolism, appetite, fat accumulation, and
inﬂammatory responses and is a potential target for treatment
of various inﬂammatory and metabolic diseases. By bioisos-
teric replacement of the central pyrrolidine core of a
previously disclosed FFA2 agonist with a synthetically more
tractable thiazolidine, we were able to rapidly synthesize and
screen analogues modiﬁed at both the 2- and 3-positions on
the thiazolidine core. Herein, we report SAR exploration of
thiazolidine FFA2 agonists and the identiﬁcation of 31 (TUG-
1375), a compound with signiﬁcantly increased potency (7-fold in a cAMP assay) and reduced lipophilicity (50-fold reduced
clogP) relative to the pyrrolidine lead structure. The compound has high solubility, high chemical, microsomal, and hepatocyte
stability, and favorable pharmacokinetic properties and was conﬁrmed to induce human neutrophil mobilization and to inhibit
lipolysis in murine adipocytes.
■ INTRODUCTION
The short-chain free fatty acid receptor FFA2 (formerly
GPR43) is a G-protein-coupled receptor that is activated by
physiological concentrations of short-chain fatty acids
(SCFAs), primarily acetate and propionate.1−5 FFA2 is
expressed in a variety of tissues including immune cells,3
adipocytes,6 pancreatic β-cells,2 and enteroendocrine L-cells.7
Colonic fermentation of dietary ﬁber produces large amounts
of SCFAs, and results indicate that an interplay between FFA2
and dietary ﬁber via colonic fermentation to produce SCFAs is
implicated in promoting a healthy composition of micro-
organisms in the gut.8 Fiber-rich diets and SCFAs can
counteract colitis,9,10 and exacerbated inﬂammation in colitis
models has been reported for FFA2-knockout mice.11
However, others have found that FFA2-knockout mice
exhibited reduced inﬂammatory responses in colitis models,12
and it is currently unclear if antagonists or agonists are
preferable for the treatment of intestinal inﬂammation. So far,
the antagonist GLPG0974 (1, Chart 1) is the only FFA2
modulator that has undergone clinical trials but unfortunately
failed to meet end points against ulcerative colitis.13
Dietary ﬁber is also known to exert positive eﬀects in
diabetic subjects.14 Acetate has been shown to potentiate
glucose-stimulated insulin secretion from β-cells in an FFA2-
dependent manner,15 and SCFAs were able to promote
secretion of the incretin glucagon-like peptide-1 (GLP-1)
from colonic cultures through FFA216 and both GLP-1 and the
appetite regulating peptide YY (PYY) in vivo,17 indicating that
activation of FFA2 could have beneﬁcial eﬀects on type 2
diabetes (T2D). Interestingly and in contrast, loss of FFA2 and
FFA3 was found to improve insulin secretion and glucose
tolerance.18 Moreover, SCFA-mediated activation of FFA2 has
been found to suppress adipose insulin signaling, leading to
reduced fat accumulation in adipose tissue, and to promote
GLP-1 secretion in the gut.19 Thus, both agonists and
antagonists of FFA2 are considered to be potential therapeutics
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for treatment of T2D and obesity.5,19−25 Several FFA2 agonists
have been disclosed, including an allosteric agonist series from
Amgen represented by 2 (known as AMG7703 or 4-CMTB)
and an orthosteric agonist series originating from Euroscreen
represented by 3.20,26−30 A recent study found that agonist 4,
also originating from Euroscreen,31 caused only marginal GLP-
1 secretion but led to signiﬁcant PYY mucosal responses,
inhibited insulin-promoted fat accumulation and intestinal
functions, and suppressed food intake, supporting FFA2 as a
possible antiobesity target.21
The FFA2 agonists disclosed hitherto have relatively high
lipophilicity, which is associated with several undesired
properties,33−35 and only moderate potency (e.g., see Chart
1). Furthermore, the allosteric agonist 2 has solubility issues
and has been reported to give results that diﬀer from
orthosteric FFA2 agonists,15 and the orthosteric agonist 3
was found to have stability issues.36 We therefore wished to
explore 4, an FFA2 agonist reported to have properties useful
for in vivo studies.21 Initially, we sought to explore the SAR
around the pyrrolidine scaﬀold of 4; however, the synthetic
route to obtain this class of FFA2 agonists is rather lengthy and
precludes eﬃcient exploration of parts of the molecule. We
therefore opted for replacing the central pyrrolidine by a
thiazolidine. This replacement strategy has previously been
employed for HIV protease inhibitors.37 Herein, we report
SAR investigations of substituted thiazolidine FFA2 agonists
and the discovery of an FFA2 agonist with improved potency,
reduced lipophilicity, and favorable physicochemical and
pharmacokinetic properties.
■ RESULTS AND DISCUSSION
Synthesis. Pyrrolidine ligands were synthesized in seven
linear steps from L-pyroglutamic acid (5, Scheme 1) essentially
as previously described by Euroscreen,31 with the modiﬁca-
tions that the ring opening by aryllithium was allowed to reach
room temperature and that the amide coupling with
pyrrolidine 6 was performed with bis(tetramethylene)-
ﬂuoroformamidinium hexaﬂuorophosphate (BTFFH).36
Thiazolidine ligands were synthesized in three steps by
condensation of (R)-Cys-OMe hydrochloride with benzalde-
hydes via 7a−j (Scheme 2). In contrast to the pyrrolidine
route, this strategy allowed rapid access also to variations on
the 2-position of the thiazolidine scaﬀold in a single step from
readily available starting materials38 and formation of the
desired (2R,4R)-thiazolidine amide as the major product in the
next step.39
Condensation of (R)-Cys-OMe hydrochloride with alde-
hydes produced mixtures of C(2) epimeric methyl (4R)-2-
arylthiazolidine-4-carboxylates (7a−j).38 To obtain the
(2R,4R)-conﬁguration, 7a−j were treated with Et3N and
subsequently reacted with the relevant acid chlorides to give
the desired (2R,4R)-products.39 Finally, demethylation using
LiI in EtOAc aﬀorded the corresponding (2R,4R)-N-
acylthiazolidine-4-carboxylic acids.39
A second set of analogues aimed at exploring the N-benzoyl
part of the ligands was synthesized from central intermediates
8a,b by Suzuki−Miyaura or Sonogashira cross-coupling
followed by demethylation, aﬀording the desired biarylic
compounds in low to good yields (Scheme 3).
The crystal structure of 14 conﬁrms unambiguously the
(2R,4R)-conﬁguration of thiazolidine substituents (Figure 1).
A relatively short intramolecular hydrogen bond of 2.598(2) Å
is found between the carboxylic acid and pyridine group. The
crystal packing (Supporting Information, Figure S1) shows no
signiﬁcant intermolecular interactions stronger than van de
Waals forces. The intramolecular hydrogen bond is a likely
reason for why crystals suitable for structural information were
Chart 1. FFA2 Modulatorsa
aclogP values are calculated using ChemBioDraw v16.0.1.4. pIC50 for 1 and pEC50 for 2 and 3 are previously reported.
28,30,32
Scheme 1. Synthesis of Pyrrolidines 4 and 37 from L-
Pyroglutamic Acida
aReagents and conditions: (a) SOCl2, MeOH, rt, 70%; (b) Boc2O,
DMAP, DCM, rt, 4 h, 98%; (c) (i) 1-iodo-2-chlorobenzene, n-BuLi,
THF, 20 min at −78 °C → rt; (ii) sat. aq NH4Cl, 67%; (d) TFA,
DCM, rt, 98%; (e) NaBH3CN, AcOH (cat.), MeOH, rt, 71% (cis/
trans 2:1, 49%/22%); (f) carboxylic acid, BTFFH, DIPEA, DCM, 80
°C, 8 h, 75%; (g) LiOH (aq), THF, rt, 42−93%.
Scheme 2. Synthesis of (2R,4R)-N-Acylthiazolidine-4-
carboxylic Acids from (R)-Cys-OMea
aReagents and conditions: (a) H2O/EtOH 1:1, KHCO3, rt, 4−24 h,
63−81%; (b) benzoyl chlorides, Et3N, −10 °C → rt, THF, 1−14 h,
21−83%; (c) LiI, EtOAc, 80 °C, 24−92%.
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obtained for this compound but for none of the others. At
physiological pH with the carboxylic acid ionized, the pyridyl
hydrogen bond will be absent and the overall conformation is
expected to be diﬀerent. It is therefore not possible to draw
conclusions regarding the conﬁguration around the amide in
the active conformation of 14. In fact, rather than the (Z)-
conﬁguration apparent in the crystal structure of 14, computer
minimizations indicate a general preference for the (E)-
conﬁguration around the amide in the compound series.
Biological Testing and SAR Analysis. Compounds were
tested on the human (h)FFA2 receptor using both a
bioluminescence resonance energy transfer (BRET)-based β-
arrestin-2 interaction assay and a cAMP inhibition assay. The
former assay is an upstream signaling assay measuring BRET
arising from agonist-mediated recruitment of β-arrestin-2 to
FFA2, and the latter assay evaluates inhibition of forskolin-
induced production of cAMP facilitated by coupling of FFA2
to Gαi/o proteins.
40
The FFA2 agonist activity of 4 was conﬁrmed in both assays.
Compound 4 has previously been reported with an EC50 of 81
nM.21 We obtained somewhat lower potencies of 1.2 μM in
the β-arrestin-2 assay and 0.53 μM in the cAMP assay. We
were pleased to ﬁnd that the thiazolidine analog 9 had only
moderately decreased potency in both the BRET and the
cAMP assay (ΔpEC50 = −0.67 and −0.31, respectively)
relative to pyrrolidine 4 (Table 1). The easy access to
substituted thiazolidines enabled a rapid screen of variations in
the 2-position of the thiazolidine scaﬀold for 2-methoxy-1,1′-
biphenyl derivatives (Table 1).
Compared to 2-chlorophenyl (9), 3-chlorophenyl (10) or 4-
chlorophenyl (11) led to a decrease in potencies in the β-
arrestin-2 assay, whereas 11 retained potency in the cAMP
assay. Thus, the 3-position appeared to be disfavored and 4-
position substitution may be a route to G-protein-biased
ligands. Substituting the 2-chloro by bromo (12) or hydrogen
(13) retained potency in both assays.
Installation of 2-pyridyl (14) or 2-furyl (15) onto the
thiazolidine scaﬀold eroded potency in the β-arrestin-2 assay
compared to the phenyl derivatives but mostly preserved
potency in the cAMP assay, again suggesting a route to G-
protein-biased agonists. Since the goal was both to increase
potency and decrease lipophilicity, values for ligand-lip-
ophilicity eﬃciency (LLE)33 based on calculated lipophilicity
of the neutral compounds (clogP) were also used to guide the
optimization. The hydrophilic pyridyl led to a marked
improvement in LLE for 14 compared to all previous
compounds including 4 but insuﬃcient potency. The
introduction of a tert-butyl group in the 2-position of the
thiazolidine scaﬀold resulted in a compound (16) that only
caused 50% receptor activation at 100 μM. Replacing sulfur
with oxygen on 16 led to a completely inactive compound
(17); hence, the oxazolidine scaﬀold was not explored further.
We next directed attention to the N-acyl substituent. As
evident from 18 (Table 2), the biphenyl system is important
for activity, as removing the terminal ring leads to complete
loss of activity. Removing only the 2′-methoxy (19) also
resulted in a pronounced loss of potency in both assays, as did
moving the terminal phenyl to the 3-position (20). The 2′-
ﬂuoro-3′-methoxy (21) and the 4′-methoxy (22) analogues
both led to decreased potency in both assays relative to the 2′-
methoxy analogue 9. Compared to 19, installation of either
acetyl (23) or nitrile (24) in the 4-position markedly boosted
Scheme 3. Synthesis of Biaryl Analogues via Coupling
Reactionsa
aReagents and conditions: (a) ArB(OH)2 or ArBPin, Pd(PPh3)4,
MeOH, toluene, 6−27 h, 20−86%; or ArCCH, Pd(PPh3)2Cl2, CuI,
Et3N, 4 h, rt, 76%; (b) LiI, EtOAc, 80 °C, 37−78%.
Figure 1. Perspective view of 14 drawn with 50% probability
ellipsoids.
Table 1. SAR Investigations at the Thiazolidine 2-Position
aBRET-based β-arrestin-2 recruitment assay. Eﬃcacy (Emax) is relative
to propionate. bcAMP FFA2 assay. Eﬃcacy (Emax) is relative to
propionate. cclogP values were calculated using ChemBioDraw
v16.0.1.4. dBRET/cAMP LLE values (LLE = pEC50 − clogP).
e50% activation at 100 μM. fNo response up to 30 μM.
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potency in both β-arresin-2 and cAMP assays, indicating that
certain hydrogen bond accepting groups are favored in this
region.
Replacing the 2′-methoxy (9) with 2′-chloro (25) or 2′-
methyl (26) resulted in a marked potency boost in the cAMP
assay for 25, whereas 2′-methoxyphenyl remained the
preferred ring system in the β-arrestin-2 assay (9 > 25 ∼ 26).
Extension of the biphenyl 19 by insertion of acetylene
between the rings (28) caused a minor loss of potency in the
cAMP assay but no changes in the β-arrestin-2 assay. In a
parallel manner, alkyne extension of 2-methoxyphenyl (9) into
29 reduced potency in the β-arrestin-2 assay but preserved
activity in the cAMP assay.
Overall, 4-biphenyl compounds with the terminal phenyl
ring carrying lipophilic (25, 26) or moderately hydrophilic (9)
substituents in the ortho-position showed higher potencies
than a nonsubstituted phenyl analogue such as 19 or 20,
indicating that a nonplanar biphenyl conformation is favored
for optimal binding of this compound class.
With this and the encouraging results from 23 and 24 in
mind, we wished to explore biaryl systems with ortho-
substituted polar heterocycles as the terminal ring. Satisfyingly,
installation of 1-methyl-1H-pyrazolyl produced a signiﬁcantly
improved compound (30), whereas introduction of 3,5-
dimethylisoxazolyl (31) appeared as the most potent
compound of the series with a pEC50 of 7.11 in the cAMP
assay and an LLE increased by 2.3 relative to the initial
pyrrolidine 4. Replacement of the methyl groups of 31 by
phenyl and cyclopropyl (32) resulted in a 40-fold lower
potency in the β-arrestin-2 assay, indicating a limit to the
acceptable steric bulk in this region.
Having identiﬁed 4-(3,5-dimethylisoxazolyl)benzoyl as a
preferred N-substituent, we directed the attention back to the
2-substituent of the thiazolidine scaﬀold to screen for
improved substituents in a second iteration (Table 3). This
eﬀort showed again that the 2-chloro (31) was clearly favored
Table 2. SAR Investigation of the N-Acyl Substituent
aBRET-based β arrestin-2 recruitment assay. Eﬃcacy (Emax) is relative
to propionate. bcAMP FFA2 assay. Eﬃcacy (Emax) is relative to
propionate. cclogP values were calculated using ChemBioDraw
v16.0.1.4. dLLE = pEC50(β-arrestin/cAMP) − clogP.
eNo response
up to 30 μM. fAverage response at highest concentration relative to
propionate.
Table 3. Variations in the 2-Position and Pyrrolidine
Analogue with the Optimized Acyl Part
aBRET-based β arrestin-2 recruitment assay. Eﬃcacy (Emax) is relative
to propionate. bcAMP FFA2 assay. Eﬃcacy (Emax) is relative to
propionate. cclogP values were calculated using ChemBioDraw
v16.0.1.4. dBRET/cAMP LLE values (LLE = pEC50 − clogP). eNo
response up to 30 μM.
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over a naked phenyl (33). The same was true for 2-ethynyl
(34) and 2-methoxy (35). Furthermore, increasing the polarity
by installation of 2-pyridyl (36) resulted in a weakly potent
agonist in the β-arrestin-2 assay, whereas 36 was devoid of any
activity when evaluated in the cAMP assay. Since pyridyl
analog 14 was a reasonably potent compound in both β-
arrestin-2 and cAMP assays, the observation that 36 lost
activity is likely explained by this compound being too polar to
eﬀectively reach the lipophilic binding site of FFA2.
As the initial idea was to use the thiazolidine as a bioisostere
for pyrrolidine in the optimization of the compound series, the
corresponding pyrrolidine 37 of thiazolidine 31 was synthe-
sized and tested (Table 3). Although pyrrolidine 37 displayed
appreciable FFA2 activity, its potency was lower than that of
31.
The occasionally diverging results in the cAMP and β-
arrestin-2 assays illustrate that potencies in the functional
assays do not directly reﬂect receptor aﬃnity. To better
understand the relationship between aﬃnity and functional
activity, we proceeded with further examination of 31 and
selected analogs in an FFA2 competition binding assay using a
radiolabeled version of antagonist 1 (Table 4). It has
previously been conﬁrmed that 1 and radiotracer [3H]-1 are
orthosteric ligands and fully displaceable by propionate and the
synthetic orthosteric agonist 3.32,41 Pyrrolidines 4 and 37 and
thiazolidines 9, 13, 19, and 31 were also all conﬁrmed to fully
displace [3H]-1. Parent pyrrolidine 4 exhibited a moderate
binding aﬃnity, and the corresponding thiazolidine (9) was
found to be a slightly stronger binder, in contrast to the slightly
lower potency observed in both functional assays. Upon
comparing 9 with the analogue lacking the 2-chloro substituent
of the 2-aryl (13) or lacking the 2′-methoxy (19) substituent at
the biphenyl system, it becomes clear that both these features
contribute signiﬁcantly to the aﬃnity (ΔpKi = 0.55 and 0.46,
respectively). The most potent thiazolidine (31) was indeed
found to also exhibit the highest binding aﬃnity within this
selection. The corresponding pyrrolidine (37) displayed a
signiﬁcantly weaker binding aﬃnity when compared to 31
(ΔpKi = −0.29), which correlated well with the observed
diﬀerences in functional potency between these two com-
pounds. Hence, for isoxazoles 31 and 37, the thiazolidine
central scaﬀold boosted both aﬃnity and receptor activation
compared to the pyrrolidine. Replacement of the 2-
methoxyphenyl (9) by the more polar 3,5-dimethylisoxazole
(31) not only gave rise to the more potent thiazolidine-based
agonist (31) but also reduced lipophilicity resulting in a
marked improvement in LLE over 4 (ΔLLE = 2.27), and 31
indeed exhibits the highest LLE of all compounds in the study.
Molecular Modeling. To better understand the inter-
action of 31 with FFA2, the compound was docked in a
previously established homology model of the receptor.32 The
lowest energy pose of 31 is depicted in Figure 2. Compound
31 was found to eﬀectively engage Arg180 and Arg255 via
ionic and hydrogen bonding interactions, an observation that is
in agreement with previous reports that both residues are
known to be vital for receptor binding and activation.30,41
Simultaneously, the carboxylate carbonyl also interacted with
the conserved Tyr238 through hydrogen bonding. The 2-
chlorophenyl moiety situated cis to the carboxylate was
observed to interact with Phe89 via displaced π−π interactions,
where the chloro substituent appears to orient the phenyl for
Table 4. Binding Aﬃnities of Compounds for FFA2
compd pKi
a
4 6.32 ± 0.02
9 6.47 ± 0.06
13 5.92 ± 0.08
19 6.01 ± 0.02
31 6.69 ± 0.03
37 6.40 ± 0.06
aBinding aﬃnities of agonists determined using [3H]-1 in radioligand
binding assays.
Figure 2. Lowest energy pose of 31 (gray) docked into hFFA2 (gold) with strongly interacting residues shown (cyan) and hydrogen bonds
highlighted (yellow stipples). (A) Receptor as ribbon viewed from the angle of helix 4 and 5. (B) Same pose with receptor as surface viewed from
the angle of helix 3 and 4.
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optimal contact. Furthermore, the dimethylisoxazole ring
formed π−cation interactions with Lys65 and edge-to-face
π−π interactions with Trp75 (Supporting Information, Figure
S2). The shown pose also reﬂects higher energy poses. No
alternative low-energy pose was identiﬁed.
Overall, groups of 31 found in the SAR analysis to be crucial
for binding, such as 2-chlorophenyl and dimethylisoxazole,
were conﬁrmed by docking to contribute to the ligand receptor
interaction, further supporting the proposed binding pose of
31 in hFFA2. Notably, both the carboxylate and the amide
carbonyl of 31 were oriented toward the two arginine residues
and Arg255 interacted directly with both groups through
hydrogen bonds (Figure 2).
Characterization of 31. Since 31 showed the highest
potency and LLE based on calculated lipophilicity in both
functional assays and the binding assay, it was decided to
characterize its properties in further detail. Thus, 31 was tested
and conﬁrmed to be active on the murine FFA2 orthologue
(pEC50 = 6.44 ± 0.13 in the cAMP assay). The compound was
found to be inactive up to 100 μM concentration at the closely
related SCFA receptor FFA3 (formerly GPR41) and evoked
no signiﬁcant agonist or antagonist response in the long-chain
fatty acid receptors FFA1 (GPR40) and FFA4 (GPR120) or in
nuclear receptors PPARα, PPARγ, PPARδ, LXRα, and LXRβ
at 10 μM (see the Supporting Information).
Previous FFA2 ligands are generally, apart from SCFAs,
lipophilic compounds. In contrast, experimental lipophilicity of
31 (Table 5) was found to be in the lower part of the optimal
range,34 giving an LLE of 6.2 based on the cAMP assay and
measured lipophilicity. The compound also showed high
aqueous solubility and chemical stability (Table 5). Recovery
after incubation with PBS at pH 7.4 or with fasted-state
simulated gastric or intestinal ﬂuid (FaSSGF/FaSSIF) was
close to quantitative, indicating excellent chemical stability.
Investigation of metabolic stability of 31 in mouse liver
microsomes also resulted in a high recovery.
Hepatocyte stability is a better approximation to the in vivo
properties than liver microsomes since mitochondrial metab-
olism and conjugation processes also take place. Incubation of
31 with primary mouse hepatocytes gave a recovery of 72%
after 2 h and low intrinsic clearance (<8 (μL/min)/106 cells),
indicating high metabolic stability in mouse hepatocytes
(Supporting Information, Figure S3 and Table S6).
The pharmacokinetic proﬁle of 31 was investigated in mice
to establish its properties as a tool for in vivo studies, revealing
a satisfactory half-life of 2 h and a moderate to low clearance of
20.3 mL min−1 kg−1 in mice (Table 6). Oral dosing of 10 mg/
kg resulted in a maximal plasma concentration of 6.5 μM after
15 min and a bioavailability of 32%. Furthermore, ip
administration of 31 at 5 mg/kg in mice and analysis of
plasma concentrations indicated an AUC0−∞ of 60 500 (ng/
mL)·min a half-life of 82 min and thus a favorable proﬁle
relative to 4 (AUC0−∞ ≈ 25 000 (ng/mL)·min, t1/2 ≈ 50
min).21
Agonist 3 has been shown to aﬀect inﬂammatory responses
in human neutrophils via FFA2 by induction of intracellular
calcium and superoxide production.42 Propionate is known to
exert beneﬁcial anti-inﬂammatory eﬀects,9 and the elimination
of FFA2 from mice has previously been shown to cause
increased inﬂammation in tissue models.11 Although the FFA2
antagonist 1 failed to meet the end point in clinical trials with
ulcerative colitis patients, the compound was found to
modulate neutrophil recruitment,43 and the therapeutic
potential of FFA2 modulation in inﬂammatory disease is still
not clear, especially since neutrophil recruitment may have
both beneﬁcial and detrimental eﬀects.44 Hence, 31 and
propionate were examined for their ability to promote human
neutrophil migration, as it is already established that
antagonists, such as 1, can inhibit chemotaxis in vitro and
that acetate can induce chemotaxis in mouse neutrophils.45,46
Compound 31 at 1 μM signiﬁcantly induced migration of
human neutrophils at a level comparable to propionate (C3) at
a physiologically relevant concentration,47 an eﬀect that was
more than doubled at 10 μM (Figure 3).
SCFAs have been shown to inhibit lipolysis in adipocytes
mediated through FFA2 via the Gαi pathway.
48 In this study
we demonstrate that thiazolidine 31, in particular when
evaluated in cAMP assays, is a potent agonist of hFFA2 with
Table 5. Physicochemical Properties
assay 31
log D (n-octanol/PBS, pH 7.4) 0.94
aqueous solubility (PBS, pH 7.4) 182 μM
chemical stability
PBS, 37 °C, 3 weeks 97.6%
FaSSIF, 2 h 95%
FaSSGF, 2 h 100%
metabolic stability (MLM, remaining, 1 h) 82%
Table 6. Pharmacokinetic Properties in Micea
parameters 31
Intravenous Administration
t1/2 138 min
AUC0−∞ 246 000 ng min mL
−1
Vd 4050 mL kg
−1
CLtotal 20.3 mL min
−1 kg−1
Oral Administration
tmax 15 min
Cmax 2880 ng mL
−1
AUC0−∞ 156 000 ng min mL
−1
F 32%
aAdministered at 10 mg/kg po and 5 mg/kg iv in Balb/c mice.
Figure 3. Ability of propionate (C3) and 31 to induce neutrophil
migration relative to the highly potent chemotactic factor fMLP (n =
4−6): (∗) p < 0.05, (∗∗∗) p < 0.01; one-way ANOVA followed by
Dunnett post hoc test.
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retained activity at mFFA2. Therefore, 31 was evaluated for its
ability to inhibit isoproterenol-induced lipolysis in murine
adipocytes, a process known to be Gαi dependent.
48 Even
though 31 is slightly less potent on murine FFA2, 31 was, as
predicted, 50-fold more potent than propionate in inhibiting
lipolysis in isoproterenol-stimulated adipocytes (Figure 4).
■ CONCLUSION
Substitution of the central pyrrolidine of a published FFA2
agonist by a synthetically more tractable thiazolidine and rapid
screening of substituents at this scaﬀold led to the discovery of
the potent and selective FFA2 agonist 31, a compound with
lipophilicity in the lower part of the optimal range and
therefore also high LLE. The compound furthermore has
excellent solubility, high chemical, microsomal, and hepatocyte
stability, and favorable pharmacokinetic properties. Compound
31 was able to induce migration of human neutrophils and to
inhibit lipolysis in murine adipocytes. Collectively, these
properties render 31 an interesting tool compound for further
exploration of FFA2 as a potential therapeutic target for
treatment of inﬂammatory and metabolic diseases.
■ EXPERIMENTAL SECTION
Synthesis. All commercial starting materials and solvents were
used without further puriﬁcation unless otherwise stated. THF was
freshly distilled from sodium/benzophenone. MeOH was freshly
distilled from Mg. DCM was freshly distilled and stored over 4 Å
sieves. TLC was performed on TLC silica gel 60 F254 plates (Merck)
and visualized at 254 nm or by staining with ninhydrin, KMnO4, or
FeCl3 stains. Petroleum ether (PE) refers to alkanes with bp 60−80
°C. Water used in reactions was demineralized, and water used for
freeze-drying was ﬁltered Milli-Q. Puriﬁcation by ﬂash chromatog-
raphy was carried out using silica gel 60 (0.040−0.063 mm, Merck).
Test compounds suspended in Milli-Q water (1 mL/10 mg, 3 drops
MeCN) were lyophilized on a Heto Drywinner freeze-dryer. 1H and
13C NMR spectra were recorded at 400 and 101 MHz, respectively,
on a Bruker Avance III 400 at 300 K. Spectra were calibrated relative
to residual solvent peaks: 1H NMR (CDCl3), 7.26 ppm;
13C NMR
(CDCl3), 77.16 ppm;
1H NMR (DMSO-d6), 2.50 ppm;
13C NMR
(DMSO-d6), 39.52 ppm;
1H NMR (CD3OD), 3.31 ppm;
13C NMR
(CD3OD), 49.00 ppm;
1H NMR (CD2Cl2), 5.32 ppm;
13C NMR
(CD2Cl2), 53.84 ppm. Rotamer chemical shift values in
1H NMR are
marked by “∗” and have been assigned where possible. Rotamer peaks
in 1H NMR are labeled by an integral equal to that of its main partner.
1H and 13C spectra of 31 were obtained at 600 and 151 MHz,
respectively, on an Agilent NMRS 600 at the indicated temperature
(Supporting Information). High-resolution mass spectra (HRMS)
were recorded on a Bruker micrOTOF-Q II (ESI). Speciﬁc optical
rotation was recorded on Anton Paar MCP 100 polarimeter. Purity
was determined by HPLC and conﬁrmed by inspection of NMR
spectra (1H and 13C NMR). HPLC analysis was performed using a
Dionex 120 C18 column (5 μm, 4.6 mm × 150 mm); ﬂow, 1 mL/
min; 10% MeCN in water (0−1 min), 10−100% MeCN in water (1−
10 min), 100% MeCN (11−15 min), with both solvents containing
0.1% formic acid as modiﬁer; UV detection at 254 nm. All test
compounds were of ≥ 95% purity. None of the test compounds
contain substructures associated with pan-assay interfering activities
(PAINS)49 by inspection or by screening for PAINS or aggregators at
http://zinc15.docking.org/patterns/home.
Methyl (4R)-2-(2-Chlorophenyl)thiazolidine-4-carboxylate
(7a). L-Cysteine methyl ester hydrochloride (1.51 g, 8.80 mmol)
was dissolved in water (6.6 mL), and potassium bicarbonate (879 mg,
8.78 mmol) was added followed by a solution of 2-chlorobenzalde-
hyde (2.49 g, 18.1 mmol) in EtOH (6.6 mL). The reaction was stirred
at rt for 12 h, whereafter the reaction mixture was diluted with water
and extracted with DCM (×3). The combined organic phases were
washed with brine, dried over Na2SO4, concentrated in vacuo, and
puriﬁed by ﬂash chromatography (EtOAc/PE, 1:5) to give 7a as a
light yellow oil (1.68 g, 75% yield, 40% minor isomer and 60% major
isomer): Rf = 0.22 (EtOAc/PE, 1:5);
1H NMR for minor isomer (400
MHz, CDCl3) δ 7.81 (dd, J = 7.6, 1.8 Hz, 1H), 7.50−7.24 (m, 6H)
[minor and major], 6.04 (br s, 1H), 4.14−4.06 (m, 1H), 3.90 (s, 3H),
3.56 (dd, J = 10.3, 6.9 Hz, 1H), 3.24−3.14 (m, 2H) [minor and
major], 2.83 (br s, 1H); 1H NMR for major isomer (400 MHz,
CDCl3) δ 7.66 (dd, J = 7.7, 1.7 Hz, 1H), 7.50−7.23 (m, 6H) [minor
and major], 6.18 (s, 1H), 4.34 (app t, J = 6.6 Hz, 1H), 3.91 (s, 3H),
3.43 (dd, J = 10.6, 6.5 Hz, 1H), 3.24−3.16 (m, 2H) [minor and
major], 3.15 (br s, 1H); 13C NMR for mixture of diastereomers (101
MHz, CDCl3) δ 172.2, 171.7, 140.2, 136.0, 133.9, 133.1, 130.0, 129.9,
129.8, 128.7, 128.3, 127.5, 127.0, 126.7, 68.5, 67.4, 65.6, 65.1, 52.8,
52.7, 39.1, 37.6; HRMS (ESI) calcd for C11H12ClNNaO2S (M +
Na+), 280.0169; found, 280.0162.
Methyl (4R)-2-(3-Chlorophenyl)thiazolidine-4-carboxylate
(7b). The title compound was prepared as described for 7a using L-
cysteine methyl ester hydrochloride (119 mg, 1.16 mmol) and 3-
chlorobenzaldehyde (328 mg, 2.33 mmol) and obtained after ﬂash
chromatography (EtOAc/PE, 1:5) as a light yellow oil (214 mg, 71%
yield, 44% minor isomer and 56% major isomer): Rf = 0.16 (EtOAc/
PE, 1:5); 1H NMR for minor isomer (400 MHz, CDCl3) δ 7.50−7.48
(m, 1H), 7.41−7.28 (m, 4H) [minor and major], 7.25−7.20 (m, 2H)
[minor and major], 5.78 (s, 1H), 4.12 (app t, J = 6.6 Hz, 1H), 3.79 (s,
3H), 3.37 (dd, J = 10.6, 7.0 Hz, 1H), 3.18−3.06 (m, 2H) [minor and
major], 2.92 (br s, 1H); 1H NMR for major isomer (400 MHz,
CDCl3) δ 7.54−7.52 (m, 1H), 7.41−7.28 (m, 4H) [minor and
major], 7.25−7.20 (m, 2H) [minor and major], 5.50 (br s, 1H),
4.01−3.93 (m, 1H), 3.80 (s, 3H), 3.45 (dd, J = 10.3, 7.1 Hz, 1H),
3.18−3.06 (m, 2H) [minor and major], 2.62 (br s, 1H); 13C NMR for
mixture of diastereomers (101 MHz, CDCl3) δ 172.1, 171.5, 143.9,
140.4, 134.6, 134.4, 130.0, 129.74, 129.0, 128.0, 127.8, 127.1, 125.9,
125.3, 71.8, 69.9, 65.6, 64.2, 52.7, 52.7, 39.2, 38.2; HRMS (ESI) calcd
for C11H13ClNO2S (M + H
+), 258.0350; found, 258.0356.
Methyl (4R)-2-(4-Chlorophenyl)thiazolidine-4-carboxylate
(7c). The title compound was prepared as described for 7a using L-
cysteine methyl ester hydrochloride (200 mg, 1.17 mmol) and 4-
chlorobenzaldehyde (328 mg, 2.33 mmol) and obtained after ﬂash
chromatography (EtOAc/PE, 1:5) as a light yellow oil (208 mg, 69%
yield, 42% minor isomer and 58% major isomer): Rf = 0.19 (EtOAc/
PE, 1:5); 1H NMR for minor isomer (400 MHz, CDCl3) δ 7.36−7.25
(m, 4H), 5.77 (s, 1H), 4.13 (t, J = 6.5 Hz, 1H), 3.78 (s, 3H), 3.36
(dd, J = 10.6, 7.0 Hz, 1H), 3.16 (dd, J = 10.6, 6.1 Hz, 1H), 2.67 (br s,
2H) [minor and major]; 1H NMR for major isomer (400 MHz,
CDCl3) δ 7.48−7.39 (m, 4H), 5.51 (s, 1H), 3.97 (dd, J = 8.8, 7.2 Hz,
1H), 3.45 (dd, J = 10.3, 7.1 Hz, 1H), 3.79 (s, 3H), 3.10 (dd, J = 10.3,
9.0 Hz, 1H), 2.67 (br s, 2H) [minor and major]; 13C NMR for
mixture of diastereomers (101 MHz, CDCl3) δ 172.1, 171.5, 140.1,
136.8, 134.5, 133.6, 128.9, 128.9, 128.5, 128.4, 71.8, 70.0, 65.5, 64.2,
52.7, 52.6, 39.2, 38.1; HRMS (ESI) calcd for C11H13ClNO2S (M +
H+), 258.0350; found, 258.0361.
Figure 4. Inhibition of isoproterenol-induced lipolysis by propionate
(pEC50 = 3.6 ± 0.4) and 31 (pEC50 = 5.3 ± 0.6) in murine adipocytes
(n = 3−4).
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Methyl (R)-2-(Pyridin-2-yl)thiazolidine-4-carboxylate (7e).
The title compound was prepared as described for 7a using L-
cysteine methyl ester hydrochloride (200 mg, 1.16 mmol) and
picolinaldehyde (187 mg, 1.75 mmol) and obtained after ﬂash
chromatography (EtOAc/PE, 1:1) as a clear oil (165 mg, 63% yield,
45% minor isomer and 55% major isomer): Rf = 0.18 (EtOAc/PE,
1:1); 1H NMR for minor isomer (400 MHz, CDCl3) δ 8.57 (d, J = 4.8
Hz, 1H), 7.72−7.61 (m, 2H) [minor and major], 7.35−7.27 (m, 2H)
[minor and major], 7.26−7.17 (m, 2H) [minor and major], 5.85 (s,
1H), 4.56 (dd, J = 6.4, 4.6 Hz, 1H), 3.80 (s, 3H), 3.63 (br s, 2H)
[minor and major], 3.41−3.31 (m, 2H); 1H NMR for major isomer
(400 MHz, CDCl3) δ 8.63 (d, J = 4.8 Hz, 1H), 7.72−7.61 (m, 2H)
[minor and major], 7.35−7.27 (m, 2H) [minor and major], 7.26−
7.17 (m, 2H) [minor and major], 5.66 (s, 1H), 4.04 (dd, J = 9.7, 6.7
Hz, 1H), 3.83 (s, 3H), 3.63 (br s, 2H) [minor and major], 3.45 (dd, J
= 10.1, 6.7 Hz, 1H), 3.09 (t, J = 9.9 Hz, 1H); 13C NMR for mixture of
diastereomers (101 MHz, CDCl3) δ 172.2, 171.2, 158.7, 156.8, 149.9,
149.6, 136.8, 136.8, 123.4, 123.0, 122.1, 121.6, 71.6, 71.1, 66.3, 65.6,
52.6 [minor and major], 39.4, 38.7; HRMS (ESI) calcd for
C10H12N2NaO2S (M + Na
+) 247.0512, found 247.0524.
Methyl (4R)-2-(2-Methoxyphenyl)thiazolidine-4-carboxy-
late (7f). The title compound was prepared as described for 7a
using L-cysteine methyl ester hydrochloride (254 mg, 1.48 mmol) and
2-methoxybenzaldehyde (199 mg, 1.46 mmol) and obtained after
ﬂash chromatography (EtOAc/PE, 1:4) as a clear oil (297 mg, 81%
yield, 40% minor isomer and 60% major isomer): Rf = 0.21 (EtOAc/
PE, 1:4); 1H NMR for minor isomer (400 MHz, CDCl3) δ 7.42 (dd, J
= 7.6, 1.5 Hz, 1H), 7.25−7.19 (m, 1H), 7.00−6.92 (m, 2H), 5.99 (br
s, 1H), 4.25 (app t, J = 6.6 Hz, 1H), 3.85 (s, 3H), 3.79 (s, 6H) [minor
and major], 3.29 (dd, J = 10.4, 6.6 Hz, 1H), 3.06 (br s, 2H) [minor
and major], 3.12−3.00 (m, 2H) [minor and major]; 1H NMR for
major isomer (400 MHz, CDCl3) δ 7.49 (dd, J = 7.6, 1.6 Hz, 1H),
7.32−7.26 (m, 1H), 6.92−6.83 (m, 2H), 5.83 (s, 1H), 3.98−3.91 (m,
1H), 3.86 (s, 3H), 3.79 (s, 6H) [minor and major], 3.42 (dd, J = 10.1,
6.8 Hz, 1H), 3.06 (br s, 2H) [minor and major], 3.12−3.00 (m, 2H)
[minor and major]; 13C NMR for mixture of diastereomers (101
MHz, CDCl3) δ 172.3, 171.8, 157.4, 156.8, 130.1, 129.7, 128.7, 127.8,
126.2, 125.8, 120.9, 120.5, 111.2, 110.7, 67.7, 66.0, 65.8, 64.9, 55.7,
55.5, 52.51, 52.49, 39.0, 37.6; HRMS (ESI) calcd for C12H16NO3S (M
+ H+) 254.0845, found 254.0855.
Methyl (4R)-2-Phenylthiazolidine-4-carboxylate (7g). The
title compound was prepared as described for 7a using L-cysteine
methyl ester hydrochloride (327 mg, 1.91 mmol) and benzaldehyde
(288 μL, 2.83 mmol) and obtained after ﬂash chromatography
(EtOAc/PE, 1:4) as a clear oil (340 mg, 80% yield, 37% minor isomer
and 63% major isomer): Rf = 0.32 (EtOAc/PE, 1:4);
1H NMR for
minor isomer (400 MHz, CDCl3) δ 7.49−7.46 (m, 2H), 7.39−7.22
(m, 6H) [minor and major], 5.81 (s, 1H), 4.20 (app t, J = 6.1 Hz,
1H), 3.77 (s, 3H), 3.37 (dd, J = 10.6, 7.1 Hz, 1H), 3.19 (dd, J = 10.6,
5.8 Hz, 1H), 2.84 (br s, 1H); 1H NMR for major isomer (400 MHz,
CDCl3) δ 7.54−7.49 (m, 2H), 7.39−7.22 (m, 6H) [minor and
major], 5.55 (s, 1H), 4.02−3.93 (m, 1H), 3.78 (s, 3H), 3.45 (dd, J =
10.3, 7.1 Hz, 1H), 3.10 (dd, J = 10.1, 9.2 Hz, 1H), 2.66 (br s, 1H);
13C NMR for mixture of diastereomers (101 MHz, CDCl3) δ 172.2,
171.6, 141.2, 138.3, 128.73, 128.72, 128.5, 127.9, 127.5, 127.0, 72.7,
70.9, 65.6, 64.4, 52.6, 52.5, 39.3, 38.2; HRMS (ESI) calcd for
C11H13NNaO2S (M + Na
+) 246.0559, found 246.0565.
Methyl (2R,4R)-2-(2-Chlorophenyl)-3-(4-iodobenzoyl)-
thiazolidine-4-carboxylate (8a). A predried vial with 7a (926
mg, 3.59 mmol) in THF (7.4 mL, anhydrous) was cooled to −10 °C
and to it was added triethylamine (1.25 mL, 8.97 mmol) dropwise.
After stirring for 15 min at rt the solution was evaporated, the
triethylammonium salt was redissolved in THF (11 mL), and the
solution was cooled to −10 °C. 4-Iodobenzoyl chloride (1.05 g, 3.95
mmol) dissolved in THF (15 mL, anhydrous) was added dropwise,
and the reaction mixture was allowed to reach rt. After stirring at rt for
4 h the solvent was evaporated oﬀ, to the crude residue was added
water (18 mL), and the mixture was acidiﬁed with 1 M HCl (pH 2−
3) and extracted with EtOAc (×3). The organic phases were washed
with brine, dried over Na2SO4, concentrated in vacuo, and puriﬁed by
ﬂash chromatography (EtOAc/PE, 1:3) to give central intermediate
8a as a white foam (1.43 g, 82% yield): Rf = 0.21 (EtOAc/PE, 1:3);
1H NMR (400 MHz, CDCl3) δ 8.32 (d, J = 6.4 Hz, 1H), 7.64−7.47
(m, 2H), 7.40−7.31 (m, 2H), 7.30−7.22 (m, 1H), 7.07−6.91 (m,
2H), 6.17 (br s, 1H), 5.07 (app s, 1H), 3.86 (s, 3H), 3.45−3.32 (m,
1H), 3.20 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 170.3, 169.9,
138.9, 137.3, 134.1, 131.4, 129.8, 129.2, 128.5, 127.5, 127.3, 97.6,
65.8, 65.5, 52.8, 31.1; HRMS (ESI) calcd for C18H16ClINO3S (M +
H+) 487.9579, found 487.9573. [α]20D +45° (c 1.0, DCM).
Methyl (2R,4R)-2-(2-Chlorophenyl)-3-(3-iodobenzoyl)-
thiazolidine-4-carboxylate (8b). The title compound was prepared
as described for 8a using 7a (300 mg, 0.16 mmol) and 3-iodobenzoyl
chloride (347 mg, 0.13 mmol) and obtained after ﬂash chromatog-
raphy (EtOAc/PE, 1:3) as a colorless oil (237 mg, 42% yield): Rf =
0.26 (EtOAc/PE, 1:3); 1H NMR (400 MHz, CDCl3) δ 8.30 (d, J =
7.1 Hz, 1H), 7.68 (d, J = 7.3 Hz, 1H), 7.57−7.48 (m, 1H), 7.40 (t, J =
7.2 Hz, 1H), 7.35 (dd, J = 7.9, 1.3 Hz, 1H), 7.29 (d, J = 7.3 Hz, 1H),
7.24−7.17 (m, 1H), 7.01−6.91 (m, 1H), 6.15 (s, 1H), 5.13−4.96 (m,
1H), 3.89 (s, 3H), 3.47−3.32 (m, 1H), 3.32−3.15 (m, 1H); 13C
NMR (101 MHz, CDCl3) δ 170.5, 169.3, 139.7, 139.1, 136.6, 136.2,
131.6, 130.0, 129.4, 127.8, 127.6, 126.1, 93.8, 65.8, 65.6, 53.0, 31.4;
HRMS (ESI) calcd for C18H15ClINNaO3S (M + Na
+) 509.9398,
found 509.9393.
(2R,4R)-2-(2-Chlorophenyl)-3-(2′-methoxybiphenyl-4-
carbonyl)thiazolidine-4-carboxylic Acid (9). Step 1: The methyl
ester of the title compound 9a was prepared as described for 8a using
7a (100 mg, 0.39 mmol) and 2′-methoxybiphenyl-4-carbonyl chloride
(107 mg, 0.44 mmol) and obtained after ﬂash chromatography
(EtOAc/PE, 1:3) as a clear viscous oil (141 mg, 77% yield): Rf = 0.20
(EtOAc/PE, 1:3); 1H NMR (400 MHz, CDCl3) δ 8.38 (d, J = 7.0 Hz,
1H), 7.49−7.19 (m, 9H), 7.07−6.91 (m, 2H), 6.32 (br s, 1H), 5.18−
5.08 (m, 1H), 3.89 (br s, 3H), 3.76 (s, 3H), 3.45−3.34 (m, 1H),
3.27−3.18 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 171.0, 170.8,
156.5, 141.4, 139.5, 133.0, 131.7, 130.7, 129.9, 129.6, 129.4, 129.3,
129.1, 127.9, 127.4, 126.9, 121.0, 111.5, 66.1, 65.9, 55.6, 52.8, 31.3;
HRMS (ESI) calcd for C25H23ClNO4S (M + H
+) 468.1031, found
468.1028.
Step 2: Methyl ester 9a (40 mg, 86 μmol) and LiI (46 mg, 0.34
mmol) were dissolved in degassed EtOAc (120 μL), the vial was
capped, ﬂushed with argon (×3), and the reaction stirred at 80 °C in
the dark. To the reaction mixture were added water and 1 M HCl
(1:1), and extraction was with EtOAc (×3). The combined organic
phases were washed with NaHSO3, water, and brine. The organic
layers were dried over Na2SO4, concentrated in vacuo, and puriﬁed by
ﬂash chromatography (EtOAc/PE, 2:1 [1% AcOH]) to give the title
compound 9 after freeze-drying as an amorphous solid (20 mg, 51%
yield): Rf = 0.13 (EtOAc/PE, 2:1 [1% AcOH]);
1H NMR (400 MHz,
CDCl3) δ 8.03 (d, J = 6.1 Hz, 1H), 7.45−7.40 (m, 2H), 7.39−7.29
(m, 5H), 7.29−7.21 (m, 2H), 7.05−6.93 (m, 2H), 6.37 (br s, 1H),
5.28−5.16 (m, 1H), 3.77 (s, 3H), 3.50−3.35 (m, 2H); 13C NMR
(101 MHz, CDCl3) δ 172.9, 172.6, 156.6, 141.9, 138.9, 132.4, 131.7,
130.8, 130.1, 129.6, 129.5, 129.5, 129.4, 127.6, 127.0, 121.1, 111.6,
66.6, 66.1, 55.7, 31.0; HRMS (ESI) calcd for C24H20ClNNaO4S (M +
Na+) 476.0694, found 476.0680. HPLC: tR = 12.28 min, 98.4%.
[α]20D +13° (c 0.25, DCM).
(2R,4R)-2-(3-Chlorophenyl)-3-(2′-methoxybiphenyl-4-
carbonyl)thiazolidine-4-carboxylic Acid (10). Step 1: The methyl
ester of the title compound 10a was prepared as described for 8a
using 7b (100 mg, 0.39 mmol) and 2′-methoxybiphenyl-4-carbonyl
chloride (105 mg, 0.43 mmol) and obtained after ﬂash chromatog-
raphy (EtOAc/PE, 1:3) as a clear viscous oil (152 mg, 83% yield): Rf
= 0.18 (EtOAc/PE, 1:3); 1H NMR (400 MHz, CDCl3) δ 7.71−7.64
(m, 1H), 7.57 (d, J = 5.8 Hz, 1H), 7.48−7.41 (m, 4H), 7.35−7.22 (m,
4H), 7.06−6.92 (m, 2H), 6.15 (br s, 1H), 5.17 (app s, 1H), 3.85 (s,
3H), 3.79 (s, 3H), 3.47−3.14 (m, 2H); 13C NMR (400 MHz, CDCl3)
δ 171.0, 170.5, 156.5, 143.5, 141.4, 134.4, 133.5, 130.8, 129.8, 129.6,
129.5, 129.4, 128.2, 127.2, 126.9, 125.2, 121.0, 111.4, 67.8, 65.2, 55.6,
52.9, 32.0; HRMS (ESI) calcd for C25H22ClNNaO4S (M + Na
+)
490.0850, found 490.0830.
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Step 2: The title compound 10 was prepared as described for 9
using methyl ester 10a (100 mg, 0.21 mmol) and LiI (4 equiv) and
obtained after ﬂash chromatography (EtOAc/PE, 1:2 [2% AcOH])
and subsequent freeze-drying as a white amorphous powder (65 mg,
67% yield): Rf = 0.16 (EtOAc/PE, 1:2 [2% AcOH]);
1H NMR (400
MHz, CDCl3) δ 7.61−7.39 (m, 5H), 7.37−7.30 (m, 2H), 7.29−7.22
(m, 3H), 7.05−6.92 (m, 2H), 6.68 (br s, 1H), 6.16 (br s, 1H), 5.23
(app s, 1H), 3.78 (s, 3H), 3.49−3.35 (m, 2H); 13C NMR (101 MHz,
CDCl3) δ 172.5, 172.1, 156.5, 142.8, 141.9, 134.7, 132.7, 130.9, 130.0,
129.8, 129.5, 129.4, 128.5, 127.0, 124.9, 121.1, 111.5, 68.3, 65.0, 55.7,
31.6; HRMS (ESI) calcd for C24H20ClNNaO4S (M + Na
+) 476.0694,
found 476.0687. HPLC: tR = 12.10 min, 97.6%. [α]
20
D +23° (c 1.0,
DCM).
(2R,4R)-2-(4-Chlorophenyl)-3-(2′-methoxybiphenyl-4-
carbonyl)thiazolidine-4-carboxylic Acid (11). Step 1: The methyl
ester of the title compound 11a was prepared as described for 8a
using 7c (99 mg, 0.39 mmol) and 2′-methoxybiphenyl-4-carbonyl
chloride (107 mg, 0.44 mmol) and obtained after ﬂash chromatog-
raphy (EtOAc/PE, 1:3) as a clear viscous oil (131 mg, 73% yield): Rf
= 0.18 (EtOAc/PE, 1:3); 1H NMR (400 MHz, CDCl3) δ 7.63−7.57
(m, 2H), 7.47−7.42 (m, 4H), 7.36−7.20 (m, 4H), 7.09−6.92 (m,
2H), 6.17 (br s, 1H), 5.15 (app s, 1H), 3.84 (br s, 3H), 3.79 (s, 3H),
3.44−3.14 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 171.0, 170.6,
156.5, 141.3, 140.1, 133.8, 133.6, 130.8, 129.6, 129.5, 129.4, 128.7,
128.5, 126.9, 121.0, 111.4, 67.7, 65.2, 55.6, 52.9, 32.0; HRMS (ESI)
calcd for C25H23ClNO4S (M + H
+) 468.1031, found 468.1009.
Step 2: The title compound 11 was prepared as described for 9
using methyl ester 11a (44 mg, 94 μmol) and LiI (4 equiv) and
obtained after ﬂash chromatography (EtOAc/PE, 1:2 [2% AcOH])
and subsequent freeze-drying as a white amorphous powder (56 mg,
24% yield): Rf = 0.17 (EtOAc/PE, 1:2 [2% AcOH]);
1H NMR (400
MHz, CDCl3) δ 7.52−7.18 (m, 10H), 7.09−6.91 (m, 2H), 6.18 (br s,
1H), 5.22 (app s, 1H), 3.79 (s, 3H), 3.48−3.33 (m, 2H); 13C NMR
(101 MHz, CDCl3) δ 172.7, 172.0, 156.5, 141.9, 139.2, 134.2, 132.7,
130.8, 129.8, 129.5, 129.4, 128.9, 128.2, 127.0, 121.1, 111.5, 68.4,
65.2, 55.7, 31.5; HRMS (ESI) calcd for C24H20ClNNaO4S (M + Na
+)
476.0694, found 476.0688. HPLC: tR = 12.17 min, 100%. [α]
20
D +31°
(c 1.0, DCM).
(2R,4R)-2-(2-Bromophenyl)-3-(2′-methoxybiphenyl-4-
carbonyl)thiazolidine-4-carboxylic Acid (12). Step 1: Methyl
(2R,4R)-2-(2-Bromophenyl)-3-(2′-methoxybiphenyl-4-carbonyl)-
thiazolidine-4-carboxylate (7i). The thiazolidine was prepared as
described for 7a using L-cysteine methyl ester hydrochloride (201
mg, 1.17 mmol) and 2-bromobenzaldehyde (431 mg, 2.33 mmol).
Crude methyl (4R)-2-(2-bromophenyl)thiazolidine-4-carboxylate
(7i) was used without further puriﬁcation in the next step.
Step 2: Methyl (2R,4R)-2-(2-Bromophenyl)-3-(2′-methoxybiphenyl-4-
carbonyl)thiazolidine-4-carboxylate (12a). Using the crude 7i (95 mg)
and 2′-methoxybiphenyl-4-carbonyl chloride (77 mg, 0.31 mmol), the
title compound was prepared as described for 8a and obtained after
ﬂash chromatography (EtOAc/PE, 1:3) as a clear viscous oil (31 mg,
20% yield): Rf = 0.18 (EtOAc/PE, 1:3);
1H NMR (400 MHz, CDCl3)
δ 8.39 (d, J = 7.4 Hz, 1H), 7.55 (dd, J = 7.9, 1.1 Hz, 1H), 7.47−7.36
(m, 4H), 7.34−7.28 (m, 2H), 7.25−7.16 (m, 2H), 7.06−6.92 (m,
2H), 6.27 (br s, 1H), 5.17−5.07 (m, 1H), 3.90 (br s, 3H), 3.76 (s,
3H), 3.41−3.33 (m, 1H), 3.28−3.18 (m, 1H); 13C NMR (101 MHz,
CDCl3) δ 171.1, 170.8, 156.6, 141.5, 133.3, 130.8, 129.7, 129.5,
129.43, 129.35, 128.2, 128.1, 127.0, 121.1, 111.6, 68.5, 66.3, 55.7,
52.9, 31.2; HRMS (ESI) calcd for C25H23BrNO4S (M + H
+)
512.0526, found 512.0520.
Step 3: The title compound 12 was prepared as described for 9
using methyl ester 12a (31 mg, 61 μmol) and LiI (4 equiv) and
obtained after ﬂash chromatography (EtOAc/PE, 1:1 [2% AcOH])
and subsequent freeze-drying as a beige amorphous solid (16 mg, 54%
yield): Rf = 0.23 (EtOAc/PE, 1:1 [2% AcOH]);
1H NMR (400 MHz,
CDCl3) δ 8.14 (d, J = 4.4 Hz, 1H), 7.50 (d, J = 7.8 Hz, 1H), 7.41−
7.33 (m, 3H), 7.33−7.27 (m, 2H), 7.25−7.23 (m, 1H), 7.20−7.09
(m, 2H), 7.03−6.89 (m, 2H), 6.25 (br s, 1H), 5.20−5.13 (m, 1H),
3.72 (s, 3H), 3.40−3.31 (m, 2H); 13C NMR (101 MHz, CDCl3) δ
173.0, 172.6, 156.6, 141.7, 140.6, 133.3, 132.6, 130.8, 129.6, 129.5,
129.4, 128.3, 128.0, 127.0, 121.8, 121.0, 111.6, 69.2, 67.0, 55.7, 30.9;
HRMS (ESI) calcd for C24H21BrNO4S (M + H
+) 498.0369, found
498.0345. HPLC: tR = 12.36 min, 99.8%. [α]
20
D +17° (c 0.3, DCM).
(2R,4R)-3-(2′-Methoxybiphenyl-4-carbonyl)-2-phenyl-
thiazolidine-4-carboxylic Acid (13). Step 1: Methyl (2R,4R)-2-
Phenylthiazolidine-4-carboxylate (7g). The thiazolidine was prepared as
described for 7a using L-cysteine methyl ester hydrochloride (201 mg,
1.17 mmol) and benzaldehyde (247 mg, 2.33 mmol). Crude methyl
(4R)-2-phenylthiazolidine-4-carboxylate (7g) was used without
further puriﬁcation in the next step.
Step 2: Methyl (2R,4R)-3-(2′-Methoxybiphenyl-4-carbonyl)-2-phenyl-
thiazolidine-4-carboxylate (13a). Using crude 7g (105 mg) and 2′-
methoxybiphenyl-4-carbonyl chloride (128 mg, 0.52 mmol), the title
compound was prepared as described for 8a and obtained after ﬂash
chromatography (EtOAc/PE, 1:3) as a white foam (146 mg, 72%
yield): Rf = 0.18 (EtOAc/PE, 1:3);
1H NMR (400 MHz, CDCl3) δ
7.71−7.56 (m, 2H), 7.47−7.18 (m, 9H), 7.04−6.91 (m, 2H), 6.19 (br
s, 1H), 5.17 (app s, 1H), 3.83 (br s, 3H), 3.76 (s, 3H), 3.44−3.16 (m,
2H); 13C NMR (101 MHz, CDCl3) δ 171.1, 170.6, 156.5, 141.6,
141.2, 133.6, 130.8, 129.6, 129.5, 129.3, 128.5, 127.9, 127.0, 126.8,
121.0, 111.4, 68.5, 65.2, 55.6, 52.8, 31.9; HRMS (ESI) calcd for
C25H24NO4S (M + H
+) 434.1421, found 434.1412.
Step 3: The title compound 13 was prepared as described for 9
using methyl ester 13a (100 mg, 0.23 mmol) and LiI (4 equiv) and
obtained after ﬂash chromatography (EtOAc/PE, 1:2 [1% AcOH])
and subsequent freeze-drying as a white amorphous powder (67 mg,
69% yield): Rf = 0.23 (EtOAc/PE, 1:1 [1% AcOH]);
1H NMR (400
MHz, CDCl3) δ 8.79 (br s, 1H), 7.46−7.39 (m, 6H), 7.35−7.29 (m,
3H), 7.28−7.21 (m, 2H), 7.02−6.90 (m, 2H), 6.22 (br s, 1H), 5.24
(app s, 1H), 3.76 (s, 3H), 3.47−3.34 (m, 2H); 13C NMR (101 MHz,
CDCl3) δ 172.7, 172.3, 156.5, 141.7, 140.7, 132.8, 130.8, 129.6, 129.4,
128.7, 128.2, 127.0, 126.6, 121.0, 111.5, 69.1, 65.0, 55.6, 31.4; HRMS
(ESI) calcd for C24H22NO4S (M + H
+) 420.1264, found 420.1259.
HPLC: tR = 11.70 min, 97.6%. [α]
20
D +22° (c 1.0, DCM).
(2R,4R)-3-(2′-Methoxybiphenyl-4-carbonyl)-2-(pyridin-2-yl)-
thiazolidine-4-carboxylic Acid (14). Step 1: The thiazolidine was
prepared as described for 7a using L-cysteine methyl ester hydro-
chloride (150 mg, 0.87 mmol) and picolinaldehyde (187 mg, 1.75
mmol). Crude methyl (4R)-2-(pyridin-2-yl)thiazolidine-4-carboxylate
(7e) was used without further puriﬁcation in the next step.
Step 2: Methyl (2R,4R)-3-(2′-Methoxybiphenyl-4-carbonyl)-2-(pyr-
idin-2-yl)thiazolidine-4-carboxylate (14a). Using crude 7e (95 mg) and
2′-methoxybiphenyl-4-carbonyl chloride (116 mg, 0.47 mmol),
methyl ester 14a was prepared as described for 8a and obtained
after ﬂash chromatography (EtOAc/PE, 1:2→ 1:1) as a clear viscous
oil (77 mg, 42% yield): Rf = 0.35 (DCM with 2% MeOH);
1H NMR
(400 MHz, CDCl3) δ 8.53 (d, J = 4.7 Hz, 1H), 8.15−7.99 (m, 1H),
7.80−7.71 (m, 1H), 7.44−7.37 (m, 3H), 7.37−7.27 (m, 2H), 7.26−
7.16 (m, 2H), 7.05−6.91 (m, 2H), 6.18 (br s, 1H), 5.25 (app s, 1H),
3.85 (br s, 3H), 3.77 (s, 3H), 3.42−3.32 (m, 2H); 13C NMR (101
MHz, CDCl3) 171.1, 170.9, 156.5, 149.6, 141.4, 137.1, 133.4, 130.8,
129.6, 129.3, 126.9, 122.7, 121.0, 120.6, 111.4, 69.6, 65.2, 55.6, 52.8,
32.0; HRMS (ESI) calcd for C24H23N2O4S (M + H
+) 435.1373,
found 435.1395.
Step 3: The title compound 14 was prepared as described for 9
using methyl ester 14a (75 mg, 0.17 mmol) and LiI (4 equiv) and
obtained after ﬂash chromatography (EtOAc/PE, 2:1 → EtOAc [1%
AcOH]) as brown crystals (53 mg, 73% yield): Rf = 0.18 (EtOAc/PE,
2:1 [1% AcOH]); dec 114−120 °C; 1H NMR (400 MHz, CDCl3) δ
8.58 (d, J = 4.8 Hz, 1H), 7.88 (br s, 1H), 7.61−7.49 (m, 4H), 7.45−
7.39 (m, 1H), 7.37−7.30 (m, 1H), 7.29−7.13 (m, 2H), 7.07−6.95
(m, 2H), 6.63 (br s, 1H), 5.14 (app s, 1H), 3.79 (s, 3H), 3.58−3.41
(m, 2H); 13C NMR (101 MHz, CDCl3) δ 173.4, 170.1, 157.4, 156.5,
147.4, 141.7, 139.6, 133.2, 130.8, 129.9, 129.5, 129.3, 126.7, 124.3,
123.3, 121.0, 111.4, 67.6, 65.9, 55.6, 37.5; HRMS (ESI) calcd for
C23H20N2NaO4S (M + Na
+) 443.1036, found 443.1056. HPLC: tR =
10.25 min, 99.5%. [α]20D +59° (c 1.0, DCM).
(2R,4R)-2-(Furan-2-yl)-3-(2′-methoxybiphenyl-4-carbonyl)-
thiazolidine-4-carboxylic Acid (15). Step 1: Methyl (2R,4R)-2-
(Furan-2-yl)-3-thiazolidine-4-carboxylate (7j). The thiazolidine was
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prepared as described for 7a using L-cysteine methyl ester hydro-
chloride (150 mg, 0.87 mmol) and 2-furancarboxaldehyde (168 mg,
1.75 mmol). Crude methyl (4R)-2-(furan-2-yl)thiazolidine-4-carbox-
ylate (7j) was used without further puriﬁcation in the next step.
Step 2: Methyl (2R,4R)-2-(Furan-2-yl)-3-(2′-methoxybiphenyl-4-
carbonyl)thiazolidine-4-carboxylate (15a). Using crude 7j (91 mg)
and 2′-methoxybiphenyl-4-carbonyl chloride (116 mg, 0.47 mmol),
the title compound 15a was prepared as described for 8a and
obtained after ﬂash chromatography (EtOAc/PE, 1:3) as a brown
viscous oil (46 mg, 25% yield): Rf = 0.21 (EtOAc/PE, 1:3);
1H NMR
(400 MHz, CDCl3) δ 7.59−7.48 (m, 4H), 7.42−7.39 (m, 1H), 7.36−
7.31 (m, 1H), 7.29 (dd, J = 7.5, 1.7 Hz, 1H), 7.05−7.00 (m, 2H),
6.87−6.78 (m, 1H), 6.37 (dd, J = 3.1, 1.8 Hz, 1H), 6.14 (br s, 1H),
5.25−5.08 (m, 1H), 3.80 (s, 6H), 3.48−3.34 (m, 2H); 13C NMR
(101 MHz, CDCl3) δ 170.5, 156.5, 152.4, 142.8, 141.5, 133.2, 130.9,
129.7, 129.4, 127.2, 121.1, 111.5, 110.7, 109.4, 63.6, 62.7, 55.7, 52.9,
32.4; HRMS (ESI) calcd for C23H22NO5S (M + H
+) 424.1213, found
424.1222.
Step 3: The title compound 15 was prepared as described for 9
using methyl ester 15a (43 mg, 0.10 mmol) and LiI (4 equiv) and
obtained after ﬂash chromatography (EtOAc/PE, 1:2 [2% AcOH])
and subsequent freeze-drying as a whitish amorphous powder (33 mg,
80% yield): Rf = 0.18 (EtOAc/PE, 1:2 [2% AcOH]);
1H NMR (400
MHz, CDCl3) δ 7.55−7.49 (m, 4H), 7.38 (d, J = 1.3 Hz, 1H), 7.36−
7.30 (m, 1H), 7.28−7.24 (m, 1H), 7.06−6.93 (m, 2H), 6.70 (d, J =
2.8 Hz, 1H), 6.36−6.32 (m, 1H), 6.15 (br s, 1H), 5.22−5.12 (m, 1H),
3.78 (s, 3H), 3.53−3.36 (m, 2H); 13C NMR (101 MHz, CDCl3) δ
172.8, 171.7, 156.5, 151.8, 143.0, 141.9, 132.7, 130.9, 129.8, 129.47,
129.45, 127.2, 121.1, 111.5, 110.9, 109.3, 63.9, 63.0, 55.7, 31.9;
HRMS (ESI) calcd for C22H19NNaO5S (M + Na
+) 432.0876, found
432.0877. HPLC: tR = 11.84 min, 98.8%. [α]
20
D −1° (c 1.0, DCM).
(2R,4R)-2-(tert-Butyl)-3-(2′-methoxybiphenyl-4-carbonyl)-
thiazolidine-4-carboxylic Acid (16). Step 1: The methyl ester of
the title compound (16a) was prepared as described for 8a using 7d
(62 mg, 0.31 mmol) and 2′-methoxybiphenyl-4-carbonyl chloride (84
mg, 0.34 mmol) and obtained after ﬂash chromatography (DCM/PE,
1:1 → DCM → DCM/EtOAc 1:1) as a clear oil (63 mg, 50% yield):
Rf = 0.34 (EtOAc/PE, 1:3);
1H NMR (400 MHz, CDCl3) δ 7.58−
7.55 (m, 4H), 7.38−7.28 (m, 2H), 7.06−6.96 (m, 2H), 5.75 (br s,
1H), 4.93 (app s, 1H), 3.80 (s, 3H), 3.73 (s, 3H), 3.36 (dd, J = 11.6,
5.9 Hz, 1H), 3.22−3.11 (m, 1H), 1.04 (s, 9H); 13C NMR (101 MHz,
CDCl3) δ 173.1, 171.1, 156.5, 140.6, 135.0, 130.8, 129.7, 129.3, 126.8,
121.1, 111.5, 73.5, 66.0, 55.7, 52.6, 38.8, 33.7, 27.2; HRMS (ESI)
calcd for C23H27NNaO4S (M + Na
+) 436.1530, found 436.1672.
Step 2: The title compound 16 was prepared as described for 9
using methyl ester 16a (48 mg, 0.12 mmol) and LiI (4 equiv) and
obtained after ﬂash chromatography (EtOAc/PE, 1:3 [1% AcOH]) to
give a cloudy oil (28 mg, 60% yield): Rf = 0.23 (EtOAc/PE, 1:3 [1%
AcOH]); 1H NMR (400 MHz, CDCl3) δ 7.67−7.53 (m, 4H), 7.39−
7.30 (m, 2H), 7.08−6.98 (m, 2H), 5.47 (br s, 1H), 5.15−5.00 (m,
1H), 3.82 (s, 3H), 4.00−3.12 (m, 2H), 0.88 (s, 9H); 13C NMR (101
MHz, CDCl3) δ 173.8, 170.2, 155.6, 140.8, 132.0, 129.9, 129.0, 128.6,
128.3, 126.2, 120.1, 110.6, 74.1, 64.2, 54.7, 38.3, 31.1, 26.1; HRMS
(ESI) calcd for C22H25NNaO4S (M + Na
+) 422.1397, found
422.1393. HPLC: tR = 12.64 min, 99.8%. [α]
20
D −100° (c 0.5, DCM).
(2R,4R)-3-Benzoyl-2-(2-chlorophenyl)thiazolidine-4-carbox-
ylic Acid (18). Step 1: The methyl ester of the title compound (18a)
was prepared as described for 8a using 7a (156 mg, 0.60 mmol) and
benzoyl chloride (79 μL, 0.68 mmol) and obtained after ﬂash
chromatography (EtOAc/PE, 1:3) as a clear oil (125 mg, 57% yield):
Rf = 0.18 (EtOAc/PE, 1:3);
1H NMR (400 MHz, CDCl3) δ 8.36 (d, J
= 7.0 Hz, 1H), 7.45−7.13 (m, 8H), 6.20 (br s, 1H), 5.09 (app s, 1H),
3.86 (s, 3H), 3.42−3.30 (m, 1H), 3.27−3.15 (m, 1H); 13C NMR
(101 MHz, CDCl3) δ 171.0, 170.6, 139.4, 134.9, 131.6, 130.8, 129.8,
129.1, 128.3, 127.7, 127.3, 126.9, 65.9, 65.7, 52.8, 31.3; HRMS (ESI)
calcd for C18H16ClNNaO3S (M + Na
+) 384.0432, found 384.0447.
Step 2: The title compound 18 was prepared as described for 9
using methyl ester 18a (114 mg, 0.32 mmol) and LiI (4 equiv) and
obtained after ﬂash chromatography (EtOAc [1% AcOH]) and
subsequent freeze-drying as white crystals (59 mg, 53% yield): Rf =
0.18 (EtOAc [1% AcOH]); mp 166−172 °C; 1H NMR (400 MHz,
CDCl3) δ 11.39 (br s, 1H), 8.14 (d, J = 7.3 Hz, 1H), 7.43−7.30 (m,
4H), 7.30−7.18 (m, 4H), 6.22 (br s, 1H), 5.29−5.08 (m, 1H), 3.48−
3.39 (m, 1H), 3.38−3.28 (m, 1H); 13C NMR (101 MHz, CDCl3) δ
173.2, 172.2, 138.9, 134.5, 131.6, 131.2, 129.9, 129.3, 128.4, 127.6,
127.5, 127.1, 66.2, 66.0, 31.1; HRMS (ESI) calcd for
C17H14ClNNaO3S (M + Na
+) 370.0275, found 370.0285. HPLC: tR
= 11.73 min, 95.2%. [α]20D +30° (c 1.0, DCM).
(2R,4R)-3-([1,1′-Biphenyl]-4-carbonyl)-2-(2-chlorophenyl)-
thiazolidine-4-carboxylic Acid (19). Step 1: To a vial charged with
8a (99 mg, 0.20 mmol) and phenylboronic acid (25 mg, 0.20 mmol)
were added toluene (1.3 mL) and MeOH (0.7 mL). The reaction
mixture was purged with argon (×5), and to it were added Pd(PPh3)4
(12 mg, 11 μmol) and aqueous Na2CO3 (170 μL, 4.0 M). The
reaction was capped and stirred at 80 °C overnight under argon, then
treated with water and extracted with EtOAc (×3), washed with brine,
dried over Na2SO4, and concentrated in vacuo, and the methyl ester
of the title compound (19a) was obtained after ﬂash chromatography
(EtOAc/PE, 1:3) as a viscous oil (58 mg, 65% yield): Rf = 0.24
(EtOAc/PE, 1:3); 1H NMR (400 MHz, CDCl3) δ 8.40 (d, J = 7.0 Hz,
1H), 7.56−7.51 (m, 2H), 7.47−7.32 (m, 9H), 7.31−7.25 (m, 1H),
6.30 (br s, 1H), 5.21−5.09 (m, 1H), 3.90 (s, 3H), 3.43−3.36 (m,
1H), 3.28−3.18 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 170.9,
170.8, 143.8, 140.0, 133.5, 131.7, 130.0, 129.2, 129.0, 128.1, 127.9,
127.8, 127.4, 127.2, 127.0, 66.1, 65.9, 52.9, 31.3; HRMS (ESI) calcd
for C24H20ClNNaO3S (M + Na
+) 460.0745, found 460.0725.
Step 2: The title compound 19 was prepared as described for 9
using methyl ester 19a (57 mg, 0.13 mmol) and LiI (4 equiv) and
obtained after ﬂash chromatography (EtOAc/PE, 1:1 [2% AcOH])
and subsequent freeze-drying as a white amorphous powder (41 mg,
75% yield): Rf = 0.16 (EtOAc/PE, 1:1 [2% AcOH]);
1H NMR (400
MHz, CDCl3) δ 8.08 (d, J = 4.6 Hz, 1H), 7.74−7.63 (m, 1H), 7.54−
7.50 (m, 2H), 7.50−7.39 (m, 4H), 7.39−7.32 (m, 4H), 7.30−7.20
(m, 1H), 6.33 (br s, 1H), 5.24 (app s, 1H), 3.49−3.35 (m, 2H); 13C
NMR (101 MHz, CDCl3) δ 172.6, 172.3, 144.2, 139.9, 138.9, 133.0,
131.7, 130.1, 129.4, 129.0, 128.2, 127.8, 127.6, 127.3, 127.1, 66.5,
66.1, 31.0; HRMS (ESI) calcd for C23H19ClNO3S (M + H
+)
424.0769, found 424.0783. HPLC: tR = 12.33 min, 97.8%. [α]
20
D
+39° (c 1.0, DCM).
(2R,4R)-3-([1,1′-Biphenyl]-3-carbonyl)-2-(2-chlorophenyl)-
thiazolidine-4-carboxylic Acid (20). Step 1: The methyl ester of
the title compound (20a) was prepared as described for 19a using 8b
(84 mg, 0.172 mmol) and phenylboronic acid (21 mg, 0.172 mmol)
and obtained after ﬂash chromatography (EtOAc/PE, 2:3) as a clear
viscous oil (45 mg, 63% yield): Rf = 0.24 (EtOAc/PE, 2:3);
1H NMR
(400 MHz, CDCl3) δ 8.43 (d, J = 6.6 Hz, 1H), 7.65−7.52 (m, 1H),
7.49−7.24 (m, 9H), 7.18−6.99 (m, 2H), 6.26 (br s, 1H), 5.21−5.07
(m, 1H), 3.90 (s, 3H), 3.47−3.33 (m, 1H), 3.30−3.14 (m, 1H); 13C
NMR (101 MHz, CDCl3) δ 171.3, 170.7, 141.0, 139.8, 135.3, 131.8,
130.0, 129.5, 129.2, 129.1, 128.8, 128.0, 127.7, 127.6, 126.9, 126.2,
125.7, 66.0, 52.9, 31.3; HRMS (ESI) calcd for C24H20ClNNaO3S (M
+ Na+) 460.0745, found 460.0742.
Step 2: The title compound 20 was prepared as described for 9
using methyl ester 20a (41 mg, 94 μmol) and LiI (4 equiv) and
obtained after ﬂash chromatography (EtOAc/PE, 1:1 [1% AcOH])
and subsequent freeze-drying as a white amorphous powder (13 mg,
33% yield): Rf = 0.24 (EtOAc/PE, 1:1 [1% AcOH]);
1H NMR (400
MHz, CDCl3) δ 8.20−8.05 (m, 1H), 7.60 (d, J = 5.6 Hz, 1H), 7.46−
7.23 (m, 9H), 7.18−7.00 (m, 2H), 6.26 (br s, 1H), 5.20 (app s, 1H),
3.49−3.26 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 172.6 (br),
141.2, 139.7, 139.2, 134.9, 131.8, 130.1, 129.8, 129.3, 129.2, 128.9,
127.8, 126.9, 126.2, 125.8, 66.7, 66.1, 31.0; HRMS (ESI) calcd for
C23H18ClNNaO3S (M + Na
+) 446.0588, found 446.0578. HPLC: tR =
12.94 min, 97.3%. [α]20D −2° (c 0.1, DCM).
(2R,4R)-2-(2-Chlorophenyl)-3-(2′-ﬂuoro-3′-methoxybiphen-
yl-4-carbonyl)thiazolidine-4-carboxylic Acid (21). Step 1: The
methyl ester of the title compound (21a) was prepared as described
for 19a using 8a (101 mg, 0.21 mmol) and (2-ﬂuoro-3-
methoxyphenyl)boronic acid (39 mg, 0.23 mmol) and obtained
after ﬂash chromatography (EtOAc/PE, 1:4) as a clear oil (77 mg,
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76% yield): Rf = 0.25 (EtOAc/PE, 1:4);
1H NMR (400 MHz, CDCl3)
δ 8.37 (d, J = 6.7 Hz, 1H), 7.45−7.23 (m, 7H), 7.15−7.06 (m, 1H),
6.99−6.87 (m, 2H), 6.28 (br s, 1H), 5.13 (app s, 1H), 3.90 (s, 6H),
3.45−3.32 (m, 1H), 3.30−3.15 (m, 1H); 13C NMR (101 MHz,
CDCl3) δ 170.8, 170.7, 150.9, 148.4 (d, J = 11.5 Hz), 139.4, 138.3,
134.0, 131.7, 129.9, 129.2, 129.0, 128.9, 128.8, 127.9, 127.4, 127.2,
124.1 (d, J = 4.3 Hz), 121.8, 112.9, 66.0, 65.8, 56.5, 52.9, 31.3; HRMS
(ESI) calcd for C25H21ClFNNaO4S (M + Na
+) 508.0756, found
508.0767.
Step 2: The title compound 21 was prepared as described for 9
using methyl ester 21a (78 mg, 0.16 mmol) and LiI (4 equiv) and
obtained after ﬂash chromatography (EtOAc/PE, 1:2 [1% AcOH])
and subsequent freeze-drying as a white amorphous powder (28 mg,
37% yield): Rf = 0.14 (EtOAc/PE, 1:2 [1% AcOH]);
1H NMR (400
MHz, CDCl3) δ 8.04 (d, J = 5.9 Hz, 1H), 7.44−7.30 (m, 6H), 7.27−
7.21 (m, 1H), 7.10 (td, J = 8.1, 1.2 Hz, 1H), 6.96 (td, J = 8.1, 1.4 Hz,
1H), 6.93−6.89 (m, 1H), 6.32 (br s, 1H), 5.28−5.15 (m, 1H), 3.91
(s, 3H), 3.50−3.32 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 171.6,
171.2, 150.0, 147.4 (d, J = 11.8 Hz), 137.7, 132.5, 130.7, 129.1, 128.4,
128.2, 127.8, 127.7, 126.6, 126.3, 123.2 (d, J = 3.6 Hz), 120.9, 112.1,
65.4, 65.0, 55.6, 30.0; HRMS (ESI) calcd for C24H19ClFNNaO4S (M
+ Na+) 494.0600, found 494.0596. HPLC: tR = 12.60 min, 99.4%.
[α]20D +32° (c 0.4, DCM).
(2R,4R)-2-(2-Chlorophenyl)-3-(4′-methoxybiphenyl-4-
carbonyl)thiazolidine-4-carboxylic Acid (22). Step 1: The methyl
ester of the title compound (22a) was prepared as described for 19a
using 8a (96, 0.20 mmol) and (4-methoxyphenyl)boronic acid (31
mg, 0.21 mmol) and obtained after ﬂash chromatography (EtOAc/
PE, 1:3) as a clear viscous oil (42 mg, 46% yield): Rf = 0.26 (EtOAc/
PE, 1:3); 1H NMR (400 MHz, CDCl3) δ 8.38 (d, J = 7.2 Hz, 1H),
7.48 (d, J = 8.6 Hz, 2H), 7.42−7.38 (m, 3H), 7.38−7.27 (m, 4H),
6.98−6.92 (m, 2H), 6.29 (br s, 1H), 5.18−5.07 (m, 1H), 3.89 (s,
3H), 3.83 (s, 3H), 3.43−3.35 (m, 1H), 3.28−3.18 (m, 1H); 13C
NMR (101 MHz, CDCl3) δ 171.1, 170.8, 159.8, 143.4, 139.6, 132.8,
132.5, 131.7, 130.0, 129.2, 128.3, 127.8, 127.4, 126.4, 114.4, 66.1,
66.0, 55.5, 52.9, 31.3; HRMS (ESI) calcd for C25H22ClNNaO4S (M +
Na+) 490.0850, found 490.0861.
Step 2: The title compound 22 was prepared as described for 9
using methyl ester 22a (41 mg, 87 μmol) and LiI (4 equiv) and
obtained after ﬂash chromatography (EtOAc/PE, 1:2 [2% AcOH])
and subsequent freeze-drying as a white amorphous powder (29 mg,
73% yield): Rf = 0.32 (EtOAc/PE, 1:2 [2% AcOH]);
1H NMR (400
MHz, CDCl3) δ 8.09 (d, J = 5.8 Hz, 1H), 7.46−7.41 (m, 2H), 7.39−
7.29 (m, 6H), 7.26−7.21 (m, 1H), 6.96−6.89 (m, 2H), 6.30 (br s,
1H), 5.26−5.13 (m, 1H), 3.83 (s, 3H), 3.44−3.31 (m, 2H); 13C
NMR (101 MHz, CDCl3) δ 172.8, 172.4, 159.9, 143.7, 139.0, 132.3,
131.6, 130.1, 129.4, 128.4, 127.9, 127.6, 126.5, 114.5, 66.6, 66.3, 55.5,
30.9; HRMS (ESI) calcd for C24H20ClNNaO4S (M + Na
+) 476.0694,
found 476.0693. HPLC: tR = 12.79 min, 100%. [α]
20
D +47° (c 0.4,
DCM).
( 2R , 4R ) -3 - ( 4 ′ -Ace ty lb ipheny l -4 - ca rbony l ) - 2 - ( 2 -
chlorophenyl)thiazolidine-4-carboxylic Acid (23). Step 1: The
methyl ester of the title compound (23a) was prepared as described
for 19a using 8a (88 mg, 0.18 mmol) and (4-acetylphenyl)boronic
acid (32 mg, 0.19 mmol) and obtained after ﬂash chromatography
(EtOAc/PE, 1:2) as a white solid (42 mg, 48% yield): Rf = 0.22
(EtOAc/PE, 1:2); 1H NMR (400 MHz, CDCl3) δ 8.39 (d, J = 6.4 Hz,
1H), 8.03−7.98 (m, 2H), 7.62 (d, J = 8.2 Hz, 2H), 7.51−7.45 (m,
2H), 7.44−7.38 (m, 2H), 7.35 (dd, J = 7.9, 1.2 Hz, 2H), 7.29 (d, J =
7.2 Hz, 1H), 6.26 (br s, 1H), 5.20−5.06 (m, 1H), 3.90 (s, 3H), 3.45−
3.36 (m, 1H), 3.29−3.18 (m, 1H), 2.62 (s, 3H); 13C NMR (101
MHz, CDCl3) δ 197.7, 170.7, 144.5, 142.4, 139.4, 136.5, 134.4, 131.7,
130.0, 129.3, 129.1, 127.9, 127.5, 127.4, 127.2, 66.1, 65.9, 53.0, 31.3,
26.8; HRMS (ESI) calcd for C26H23ClNO4S (M + H
+) 480.1031,
found 480.1054.
Step 2: The title compound 23 was prepared as described for 9
using methyl ester 23a (42 mg, 86 μmol) and LiI (4 equiv) and
obtained after ﬂash chromatography (EtOAc/PE, 1:1 [2% AcOH])
and subsequent freeze-drying as a white solid (31 mg, 78% yield): Rf =
0.17 (EtOAc/PE, 1:1 [2% AcOH]); mp 202−208 °C; 1H NMR (400
MHz, CDCl3) δ 8.14 (d, J = 5.0 Hz, 1H), 7.97 (d, J = 8.3 Hz, 2H),
7.55 (d, J = 7.9 Hz, 2H), 7.47−7.39 (m, 2H), 7.39−7.29 (m, 4H),
7.29−7.21 (m, 1H), 6.26 (br s, 1H), 5.26−5.11 (m, 1H), 3.48−3.31
(m, 2H), 2.62 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 197.8, 172.7,
172.0, 144.3, 142.7, 139.0, 136.6, 134.0, 131.6, 130.1, 129.4, 129.1,
128.0, 127.6, 127.4, 127.3, 66.5, 31.0, 26.8; HRMS (ESI) calcd for
C25H20ClNNaO4S (M + Na
+) 488.0694, found 488.0695. HPLC: tR =
12.18 min, 95.7%. [α]20D +64° (c 0.4, DCM).
(2R ,4R)-2-(2-Chlorophenyl)-3-(4′-cyanobiphenyl-4-
carbonyl)thiazolidine-4-carboxylic Acid (24). Step 1: The methyl
ester of the title compound (24a) was prepared as described for 19a
using 8a (81 mg, 0.17 mmol) and (4-cyanophenyl)boronic acid (26
mg, 0.18 mmol) and obtained after ﬂash chromatography (EtOAc/
PE, 2:7) as a white viscous oil (31 mg, 41% yield): Rf = 0.27 (EtOAc/
PE, 1:3); 1H NMR (400 MHz, CDCl3) δ 8.38 (d, J = 6.4 Hz, 1H),
7.74−7.70 (m, 2H), 7.64−7.60 (m, 2H), 7.49−7.33 (m, 6H), 7.32−
7.28 (m, 1H), 6.24 (br s, 1H), 5.24−5.06 (m, 1H), 3.91 (s, 3H),
3.47−3.37 (m, 1H), 3.29−3.16 (m, 1H); 13C NMR (101 MHz,
CDCl3) δ 170.6, 170.5, 144.5, 141.6, 139.4, 134.9, 132.8, 131.7, 130.0,
129.4, 128.0, 127.9, 127.5, 127.2, 118.8, 111.8, 66.0, 65.8, 53.0, 31.3;
HRMS (ESI) calcd for C25H19ClN2NaO3S (M + Na
+) 485.0697,
found 485.0696.
Step 2: The title compound 24 was prepared as described for 9
using methyl ester 24a (31 mg, 67 μmol) and LiI (4 equiv) and
obtained after ﬂash chromatography (EtOAc/PE, 1:2 [2% AcOH])
and subsequent freeze-drying as a white amorphous powder (21 mg,
69% yield): Rf = 0.15 (EtOAc/PE, 1:2 [2% AcOH]);
1H NMR (400
MHz, CDCl3) δ 8.13 (d, J = 6.0 Hz, 1H), 7.73−7.67 (m, 2H), 7.61−
7.55 (m, 2H), 7.46−7.31 (m, 6H), 7.29−7.21 (m, 1H), 6.25 (br s,
1H), 5.24−5.14 (m, 1H), 3.47−3.39 (m, 1H), 3.39−3.31 (m, 1H);
13C NMR (101 MHz, CDCl3) δ 172.7, 171.7, 144.3, 141.9, 138.9,
134.5, 132.8, 131.6, 130.1, 129.5, 128.1, 127.9, 127.6, 127.3, 118.7,
111.9, 66.4, 66.3, 31.0; HRMS (ESI) calcd for C24H17ClN2NaO3S (M
+ Na+) 471.0541, found 471.0554. HPLC: tR = 12.30 min, 95.8%.
[α]20D +59° (c 0.5, DCM).
( 2R , 4R ) - 3 - (2 ′ -Ch lo rob ipheny l -4 - ca rbony l ) -2 - (2 -
chlorophenyl)thiazolidine-4-carboxylic Acid (25). Step 1: The
methyl ester of the title compound (25a) was prepared as described
for 19a using 8a (98 mg, 0.20 mmol) and (2-chlorophenyl)boronic
acid (34 mg, 0.22 mmol) and obtained after ﬂash chromatography
(EtOAc/PE, 1:5) as a viscous oil (80 mg, 84% yield): Rf = 0.16
(EtOAc/PE, 1:5); 1H NMR (400 MHz, CDCl3) δ 8.37 (d, J = 6.9 Hz,
1H), 7.60−7.12 (m, 11H), 6.30 (br s, 1H), 5.21−5.07 (m, 1H), 3.90
(s, 3H), 3.44−3.33 (m, 1H), 3.29−3.19 (m, 1H); 13C NMR (101
MHz, CDCl3) δ 170.8, 170.7, 141.9, 139.5, 139.3, 133.9, 132.4, 131.7,
131.2, 130.1, 129.9, 129.4, 129.2, 129.1, 127.9, 127.4, 127.0, 126.8,
65.9, 65.7, 52.9, 31.4; HRMS (ESI) calcd for C24H20Cl2NO3S (M +
H+) 472.0535, found 472.0576.
Step 2: The title compound 25 was prepared as described for 9
using methyl ester 25a (81 mg, 0.17 mmol) and LiI (4 equiv) and
obtained after ﬂash chromatography (EtOAc/PE, 1:2 [1% AcOH])
and subsequent freeze-drying as a white amorphous powder (56 mg,
72% yield): Rf = 0.19 (EtOAc/PE, 1:2 [1% AcOH]);
1H NMR (400
MHz, CDCl3) δ 8.29 (br s, 1H), 8.08 (d, J = 5.4 Hz, 1H), 7.46−7.42
(m, 1H), 7.39−7.21 (m, 10H), 6.34 (br s, 1H), 5.31−5.16 (m, 1H),
3.66−3.29 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 172.8, 172.2,
142.4, 139.4, 138.7, 133.5, 132.5, 131.7, 131.2, 130.2, 130.1, 129.6,
129.4, 129.2, 127.6, 127.3, 127.0, 126.9, 66.3, 66.0, 31.3; HRMS (ESI)
calcd for C23H17Cl2NNaO3S (M + Na
+) 480.0198, found 480.0186.
HPLC: tR = 13.33 min, 96.8%. [α]
20
D +73° (c 1.0, MeOH).
(2R ,4R)-2-(2-Chlorophenyl)-3-(2′-methylbiphenyl-4-
carbonyl)thiazolidine-4-carboxylic Acid (26). Step 1: The methyl
ester or the title compound (26a) was prepared as described for 19a
using 8a (100 mg, 0.21 mmol) and o-tolylboronic acid (31 mg, 0.23
mmol) and obtained after ﬂash chromatography (EtOAc/PE, 1:5) as
a clear viscous oil (81 mg, 86% yield): Rf = 0.25 (EtOAc/PE, 1:5);
1H
NMR (400 MHz, CDCl3) δ 8.38 (d, J = 7.3 Hz, 1H), 7.41−7.35 (m,
1H), 7.32−7.11 (m, 10H), 6.30 (br s, 1H), 5.14 (app s, 1H), 3.90 (s,
3H), 3.45−3.33 (m, 1H), 3.31−3.22 (m, 1H), 2.17 (s, 3H); 13C
NMR (101 MHz, CDCl3) δ 171.0, 170.7, 144.6, 140.8, 139.4, 135.3,
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133.3, 131.6, 130.5, 129.8, 129.6, 129.2, 129.1, 127.9, 127.8, 127.4,
126.8, 125.9, 65.8, 65.7, 52.9, 31.5, 20.3; HRMS (ESI) calcd for
C25H22ClNNaO3S (M + Na
+) 474.0901, found 474.0922.
Step 2: The title compound 26 was prepared as described for 9
using methyl ester 26a (81 mg, 0.18 mmol) and LiI (4 equiv) and
obtained after ﬂash chromatography (EtOAc/PE, 1:3 [1% AcOH])
and subsequent freeze-drying as a white amorphous powder (54 mg,
54% yield): Rf = 0.24 (EtOAc/PE, 1:3 [1% AcOH]);
1H NMR (400
MHz, CDCl3) δ 8.11 (d, J = 7.2 Hz, 1H), 8.04 (br s, 1H), 7.56−6.99
(m, 11H), 6.34 (br s, 1H), 5.37−5.14 (m, 1H), 3.51−3.34 (m, 2H),
2.17 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 172.0, 171.3, 144.0,
139.8, 137.9, 134.3, 131.8, 130.6, 129.5, 128.9, 128.6, 128.4, 128.3,
126.9, 126.7, 126.6, 125.9, 125.0, 65.2, 64.9, 30.2, 19.4; HRMS (ESI)
calcd for C24H20ClNNaO3S (M + Na
+) 460.0745, found 460.0738.
HPLC: tR = 13.53 min, 97.2%. [α]
20
D +38° (c 1.0, DCM).
(2R,4R)-2-(2-Chlorophenyl)-3-(4-(5-methylthiophen-2-yl)-
benzoyl)thiazolidine-4-carboxylic Acid (27). Step 1: The methyl
ester of the title compound (27a) was prepared as described for 19a
using 8a (106 mg, 0.22 mmol) and 5-methylthiophene-2-boronic acid
pinacol ester (51 mg, 0.23 mmol) and obtained after ﬂash
chromatography (EtOAc/PE, 1:5) as a red oil (78 mg, 78% yield):
Rf = 0.20 (EtOAc/PE, 1:5);
1H NMR (400 MHz, CDCl3) δ 8.37 (d, J
= 7.2 Hz, 1H), 7.43−7.35 (m, 5H), 7.32−7.28 (m, 2H), 7.11 (d, J =
3.5 Hz, 1H), 6.72−6.70 (m, 1H), 6.28 (br s, 1H), 5.17−5.04 (m, 1H),
3.88 (s, 3H), 3.41−3.33 (m, 1H), 3.25−3.16 (m, 1H), 2.48 (s, 3H);
13C NMR (101 MHz, CDCl3) δ 170.7, 141.0, 140.6, 139.4, 137.2,
132.8, 131.7, 130.0, 129.2, 128.0, 127.8, 127.4, 126.6, 125.0, 124.2,
66.1, 65.9, 52.9, 31.2, 15.6; HRMS (ESI) calcd for C23H21ClNO3S2
(M + H+) 458.0646, found 458.0640.
Step 2: The title compound 27 was prepared as described for 9
using methyl ester 27a (65 mg, 0.14 mmol) and LiI (4 equiv) and
obtained after ﬂash chromatography (EtOAc/PE, 1:2 [2% AcOH])
and subsequent freeze-drying as a white amorphous powder (48 mg,
75% yield): Rf = 0.27 (EtOAc/PE, 1:2 [2% AcOH]);
1H NMR (400
MHz, CDCl3) δ 8.06 (d, J = 5.9 Hz, 1H), 7.79 (br s, 1H), 7.44−7.33
(m, 4H), 7.30−7.22 (m, 3H), 7.11 (d, J = 3.6 Hz, 1H), 6.74−6.68 (m,
1H), 6.31 (br s, 1H), 5.24−5.11 (m, 1H), 3.47−3.30 (m, 2H), 2.49
(s, 3H); 13C NMR (101 MHz, CDCl3) δ 172.8, 172.1, 141.2, 140.5,
138.9, 137.7, 132.3, 131.6, 130.2, 129.4, 128.1, 127.6, 127.5, 126.6,
125.1, 124.4, 66.6, 66.2, 30.9, 15.6; HRMS (ESI) calcd for
C22H18ClNNaO3S2 (M + Na
+) 466.0309, found 466.0296. HPLC:
tR = 13.43 min, 98.6%. [α]
20
D +38° (c 1.0, DCM).
(2R,4R)-2-(2-Chlorophenyl)-3-(4-(phenylethynyl)benzoyl)-
thiazolidine-4-carboxylic Acid (28). Step 1: The methyl ester of
the title compound (28a) was prepared as described for 8a using 7a
(111 mg, 0.43 mmol) and 4-(phenylethynyl)benzoyl chloride (113
mg, 0.47 mmol) and obtained after ﬂash chromatography (EtOAc/
PE, 1:3) as a clear viscous oil (127 mg, 65% yield): Rf = 0.31 (EtOAc/
PE, 1:3); 1H NMR (400 MHz, CDCl3) δ 8.35 (d, J = 7.0 Hz, 1H),
7.53−7.45 (m, 2H), 7.41−7.19 (m, 10H), 6.21 (br s, 1H), 5.10 (app
s, 1H), 3.87 (s, 3H), 3.46−3.30 (m, 1H), 3.29−3.13 (m, 1H); 13C
NMR (101 MHz, CDCl3) δ 170.5, 170.4, 139.2, 134.2, 133.1, 131.7,
131.4, 129.9, 129.2, 128.7, 128.4, 127.7, 127.4, 127.1, 126.0, 122.7,
91.6, 88.5, 65.9, 65.7, 52.8, 31.2; HRMS (ESI) calcd for
C26H21ClNO3S (M + H
+) 462.0925, found 462.0938.
Step 2: The title compound 28 was prepared as described for 9
using methyl ester 28a (83 mg, 0.18 mmol) and LiI (4 equiv) and
obtained after ﬂash chromatography (EtOAc/PE, 1:2 [2% AcOH])
and subsequent freeze-drying as a white amorphous powder (67 mg,
83% yield): Rf = 0.25 (EtOAc/PE, 1:2 [2% AcOH]);
1H NMR (400
MHz, CDCl3) δ 8.13 (d, J = 7.3 Hz, 1H), 8.04−7.93 (m, 1H), 7.52−
7.47 (m, 2H), 7.42−7.32 (m, 7H), 7.29−7.23 (m, 2H), 6.24 (br s,
1H), 5.23−5.15 (m, 1H), 3.50−3.42 (m, 1H), 3.38−3.30 (m, 1H);
13C NMR (101 MHz, CDCl3) δ 173.0, 171.6, 138.8, 133.7, 131.8,
131.6, 130.1, 129.4, 128.8, 128.5, 127.6, 127.5, 127.3, 126.5, 122.8,
91.9, 88.5, 66.3, 66.1, 31.0; HRMS (ESI) calcd for C25H18ClNNaO3S
(M + Na+) 470.0588, found 470.0597. HPLC: tR = 13.58 min, 98.7%.
[α]20D +61° (c 1.0, DCM).
(2R,4R)-2-(2-Chlorophenyl)-3-(4-((2-methoxyphenyl)-
ethynyl)benzoyl)thiazolidine-4-carboxylic Acid (29). Step 1: To
a predried vial charged with 8a (72 mg, 0.15 mmol) and 1-ethynyl-2-
methoxybenzene (26 mg, 0.19 mmol) was added THF (1.2 mL,
anhydrous). The reaction mixture was purged with argon (×3), and to
it were added Pd(PPh3)2Cl2 (6 mg, 9.0 μmol), CuI (4 mg, 22 μmol),
and Et3N (81 μL, 0.58 mmol). The reaction was capped and stirred at
rt for 4 h under argon, whereafter the mixture was concentrated in
vacuo. The methyl ester 29a was obtained after ﬂash chromatography
(EtOAc/PE, 1:3) as a white oil (55 mg, 76% yield): Rf = 0.17
(EtOAc/PE, 1:3); 1H NMR (400 MHz, CDCl3) δ 8.35 (d, J = 7.1 Hz,
1H), 7.46 (dd, J = 7.6, 1.5 Hz, 1H), 7.44−7.34 (m, 4H), 7.34−7.23
(m, 4H), 6.97−6.84 (m, 2H), 6.21 (br s, 1H), 5.10 (app s, 1H), 3.89
(s, 6H), 3.43−3.34 (m, 1H), 3.27−3.18 (m, 1H); 13C NMR (101
MHz, CDCl3) δ 170.7, 160.1, 139.4, 134.0, 133.8, 131.5, 130.3, 130.0,
129.3, 127.7, 127.4, 127.1, 126.5, 120.6, 112.0, 110.8, 92.6, 88.2, 66.1,
65.9, 55.9, 53.0, 31.2; HRMS (ESI) calcd for C27H22ClNNaO4S (M +
Na+) 514.0850, found 514.0766.
Step 2: The title compound 29 was prepared as described for 9
using methyl ester 29a (55 mg, 0.11 mmol) and LiI (4 equiv) and
obtained after ﬂash chromatography (EtOAc/PE, 1:1 [1% AcOH])
and subsequent freeze-drying as a white amorphous powder (39 mg,
72% yield): Rf = 0.23 (EtOAc/PE, 1:1 [1% AcOH]);
1H NMR (400
MHz, CDCl3) δ 8.06 (d, J = 6.6 Hz, 1H), 7.50−7.21 (m, 9H), 6.98−
6.86 (m, 2H), 6.25 (br s, 1H), 5.25−5.08 (m, 1H), 3.90 (s, 3H),
3.47−3.40 (m, 1H), 3.40−3.33 (m, 1H); 13C NMR (101 MHz,
CDCl3) δ 172.8, 171.9, 160.2, 138.8, 133.8, 133.5, 131.6, 130.4, 130.2,
129.5, 128.0, 127.6, 127.5, 127.2, 126.9, 120.7, 112.0, 110.9, 92.5,
88.5, 66.4, 66.1, 56.0, 30.9; HRMS (ESI) calcd for C26H20ClNNaO4S
(M + Na+) 500.0694, found 500.0714. HPLC: tR = 13.23 min, 96.2%.
[α]20D +68° (c 1.0, DCM).
(2R,4R)-2-(2-Chlorophenyl)-3-(4-(1-methyl-1H-pyrazol-5-yl)-
benzoyl)thiazolidine-4-carboxylic Acid (30). Step 1: The methyl
ester of the title compound (30a) was prepared as described for 19a
using 8a (93 mg, 0.19 mmol) and 1-methyl-1H-pyrazole-5-boronic
acid pinacol ester (41 mg, 0.19 mmol) and obtained after ﬂash
chromatography (EtOAc/PE, 1:1) as a clear viscous oil (17 mg, 20%
yield): Rf = 0.17 (EtOAc/PE, 1:1);
1H NMR (400 MHz, CDCl3) δ
8.36 (d, J = 6.7 Hz, 1H), 7.48 (d, J = 1.8 Hz, 1H), 7.43−7.21 (m,
7H), 6.28 (d, J = 1.5 Hz, 1H), 6.24 (br s, 1H), 5.18−5.06 (m, 1H),
3.90 (s, 3H), 3.82 (s, 3H), 3.46−3.37 (m, 1H), 3.30−3.20 (m, 1H);
13C NMR (101 MHz, CDCl3) δ 170.6, 170.4, 142.5, 139.2, 138.7,
134.8, 133.1, 131.6, 130.0, 129.4, 128.6, 128.0, 127.54, 127.45, 106.5,
65.9, 65.6, 53.0, 37.6, 31.4; HRMS (ESI) calcd for C22H21ClN3O3S
(M + H+) 442.0987, found 442.1007.
Step 2: The title compound 30 was prepared as described for 9
using methyl ester 30a (17 mg, 39 μmol) and LiI (4 equiv) and
obtained after ﬂash chromatography (EtOAc [1% AcOH]) and
subsequent freeze-drying as a white amorphous powder (12 mg, 71%
yield): Rf = 0.14 (EtOAc [1% AcOH]);
1H NMR (400 MHz, CDCl3)
δ 8.28 (d, J = 7.2 Hz, 1H), 7.55 (d, J = 1.9 Hz, 1H), 7.40−7.21 (m,
7H), 6.29 (d, J = 1.2 Hz, 1H), 6.25 (br s, 1H), 5.26−5.15 (m, 1H),
3.84 (s, 3H), 3.52−3.43 (m, 1H), 3.42−3.32 (m, 1H); 13C NMR
(101 MHz, CDCl3) δ 172.4, 171.1, 142.8, 139.1, 138.5, 134.9, 132.9,
131.5, 129.9, 129.4, 128.7, 128.0, 127.6, 125.4, 106.6, 66.2, 66.1, 37.4,
31.4; HRMS (ESI) calcd for C21H19ClN3O3S (M + H
+) 428.0830,
found 428.0836. HPLC: tR = 10.84 min, 98.1%. [α]
20
D +31° (c 0.2,
DCM).
(2R,4R)-2-(2-Chlorophenyl)-3-(4-(3,5-dimethylisoxazol-4-
yl)benzoyl)thiazolidine-4-carboxylic Acid (31). Step 2: The
methyl ester of the title compound (31a) was prepared as described
for 19a using 8a (106 mg, 0.22 mmol) and 3,5-dimethylisoxazole-4-
boronic acid pinacol ester (51 mg, 0.23 mmol) and obtained after
ﬂash chromatography (EtOAc/PE, 1:3) as white needles (63 mg, 63%
yield): Rf = 0.14 (EtOAc/PE, 1:3); mp 146−148 °C; 1H NMR (400
MHz, CDCl3) δ 8.36 (d, J = 6.9 Hz, 1H), 7.44−7.36 (m, 1H), 7.36−
7.22 (m, 4H), 7.19−7.01 (m, 2H), 6.25 (br s, 1H), 5.20−5.08 (m,
1H), 3.91 (s, 3H), 3.48−3.38 (m, 1H), 3.33−3.22 (m, 1H), 2.35 (s,
3H), 2.21 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 170.6, 165.7,
158.4, 139.2, 134.0, 133.1, 131.5, 129.8, 129.3, 128.9, 128.0, 127.5,
115.9, 65.8, 65.5, 52.9, 31.5, 11.6, 10.7; HRMS (ESI) calcd for
C23H21ClN2NaO4S (M + Na
+) 479.0803, found 479.0812.
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Step 2: The title compound 31 was prepared as described for 9
using methyl ester 31a (61 mg, 0.13 mmol) and LiI (4 equiv) and
obtained after ﬂash chromatography (EtOAc/PE, 1:2 → EtOAc [2%
AcOH]) and subsequent freeze-drying gave 31 as a powder (25 mg,
42% yield): Rf = 0.21 (EtOAc/PE, 1:2 [2% AcOH]);
1H NMR (600
MHz, DMSO-d6, 100 °C) δ 8.35 (dd, J = 7.8, 1.0 Hz, 1H), 7.42−7.34
(m, 3H), 7.33−7.29 (m, 1H), 7.29−7.26 (m, 3H), 6.41 (s, 1H), 5.02
(t, J = 6.5 Hz, 1H), 3.62 (dd, J = 12.0, 6.6 Hz, 1H), 3.30 (dd, J = 12.1,
6.4 Hz, 1H), 2.35 (s, 3H), 2.17 (s, 3H); 13C NMR (151 MHz,
DMSO-d6, 100 °C) δ 170.5, 168.9, 164.8, 157.3, 138.2, 134.6, 131.3,
130.6, 128.62, 128.55, 128.1, 127.7, 126.7, 126.3, 114.9, 64.9, 63.9,
32.1, 10.5, 9.5; HRMS (ESI) calcd for C22H19ClN2NaO4S (M + Na
+)
465.0646, found 465.0627. HPLC: tR = 11.65 min, 98.3%. [α]
20
D
+72° (c 0.5, MeOH).
(2R,4R)-2-(2-Chlorophenyl)-3-(4-(5-cyclopropyl-3-phenyli-
soxazol-4-yl)benzoyl)thiazolidine-4-carboxylic Acid (32). Step
1: Methyl (2R,4R)-2-(2-Chlorophenyl)-3-(4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)benzoyl)thiazolidine-4-carboxylate. In a vial, a
mixture of 8a (120 mg, 0.25 mmol), bis(pinacolato)diboron (69
mg, 0.27 mmol), and potassium acetate (61 mg, 0.62 mmol) in DMF
(0.35 mL) was purged with argon (×5), followed by the addition of
1,1′-bis(phenylphosphino)ferrocene palladium dichloride (9.0 mg,
12.30 μmol), and the mixture was again purged with argon (×5). The
reaction was capped and stirred at 50 °C under argon until
consumption of starting material (20 h). The reaction was treated
with water and extracted with EtOAc (×5), washed with brine, dried
over Na2SO4, and concentrated in vacuo.
Step 2: 5-Cyclopropyl-4-iodo-3-phenylisoxazole. To (Z)-3-cyclo-
propyl-1-phenylprop-2-yn-1-one O-methyl oxime (69 mg, 0.35
mmol) dissolved in dry DCM (3.5 mL) was added IBr (143 mg,
0.69 mmol), and the reaction was stirred at rt until consumption of
starting material. The reaction mixture was washed with saturated
Na2S2O3, extracted with DCM (×5), dried over Na2SO4, and
concentrated in vacuo. The crude 5-cyclopropyl-4-iodo-3-phenyl-
isoxazole was ﬁltered through a plug of silica using PE (1% EtOAc)
and used without further puriﬁcation in the next step.
Step 3: Methyl (2R,4R)-2-(2-Chlorophenyl)-3-(4-(5-cyclopropyl-3-
phenylisoxazol-4-yl)benzoyl)thiazolidine-4-carboxylate (32a). In a vial,
to crude boronate from step 1 (100 mg) were added crude 5-
cyclopropyl-4-iodo-3-phenylisoxazole (55 mg, 0.18 mmol) and XPhos
Pd G4 precatalyst (3.8 mg, 4.4 μmol). The vial was capped and
purged with argon (×5). Reactants were dissolved in THF (0.41 mL,
degassed), after which K3PO4 (0.82 mL, 0.5 M, degassed) was added
and the reaction was stirred at 80 °C for 5 h under argon. The
reaction was treated with water and extracted with EtOAc (×5),
washed with brine, dried over Na2SO4, and concentrated in vacuo.
The title compound was obtained after ﬂash chromatography
(EtOAc/PE, 1:3) as a cloudy viscous oil (25 mg, 26% yield): Rf =
0.20 (EtOAc/PE, 1:3); 1H NMR (400 MHz, CDCl3) δ 8.34 (d, J =
7.3 Hz, 1H), 7.41−7.28 (m, 8H), 7.27−7.22 (m, 2H), 7.17−7.06 (m,
2H), 6.23 (s, 1H), 5.17−5.03 (m, 1H), 3.90 (s, 3H), 3.41 (dd, J = 6.4,
12.1 Hz, 1H), 3.29−3.19 (m, 1H), 1.98−1.89 (m, 1H), 1.20−1.12
(m, 2H), 1.06−0.97 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 170.9,
170.6, 161.2, 139.4, 134.1, 133.3, 131.5, 129.9, 129.9, 129.6, 129.3,
128.8, 128.7, 128.5, 127.9, 127.5, 127.4, 114.4, 65.9, 65.8, 53.0, 31.4,
8.4, 7.8; HRMS (ESI) calcd for C30H25ClN2O4S (M + H
+) 545.1296,
found 545.1309.
Step 4: The title compound 32 was prepared as described for 9
using methyl ester 32a (27 mg, 49 μmol) and LiI (4 equiv) and
obtained after ﬂash chromatography (EtOAc/PE, 1:1 [1% AcOH])
and subsequent freeze-drying as a white amorphous powder (19 mg,
75% yield): Rf = 0.17 (EtOAc/PE, 1:1 [1% AcOH]);
1H NMR (400
MHz, CDCl3) δ 8.08 (d, J = 6.8 Hz, 1H), 7.40−7.27 (m, 8H), 7.25−
7.19 (m, 2H), 7.18−7.09 (m, 2H), 6.27 (s, 1H), 5.25−5.12 (m, 1H),
3.52−3.32 (m, 2H), 1.99−1.87 (m, 1H), 1.20−1.14 (m, 2H), 1.05−
0.99 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 172.7, 172.0, 171.0,
161.2, 138.9, 133.6, 131.5, 130.01, 129.95, 129.7, 129.5, 128.7, 128.5,
127.6, 127.4, 114.3, 66.3, 66.0, 31.2, 8.5, 7.8; HRMS (ESI) calcd for
C29H23ClN2O4S (M + Na
+) 553.0959, found 553.0965. HPLC: tR =
13.58 min, 98.8%.
(2R,4R)-3-(4-(3,5-Dimethylisoxazol-4-yl)benzoyl)-2-phenyl-
thiazolidine-4-carboxylic Acid (33). Step 1: The methyl ester of
the title compound (33a) was prepared as described for 8a using 7g
(55 mg, 0.25 mmol) and 4-(3,5-dimethylisoxazol-4-yl)benzoyl
chloride (64 mg, 0.27 mmol) and obtained after ﬂash chromatography
(EtOAc/PE, 2:5) as a clear viscous oil (30 mg, 29% yield): Rf = 0.22
(EtOAc/PE, 1:1); 1H NMR (400 MHz, CDCl3) δ 7.65−7.54 (m,
2H), 7.45−7.36 (m, 2H), 7.36−7.30 (m, 2H), 7.30−7.24 (m, 1H),
7.19−7.05 (m, 2H), 6.09 (br s, 1H), 5.19 (app s, 1H), 3.86 (s, 3H),
3.50−3.23 (m, 2H), 2.36 (s, 3H), 2.22 (s, 3H); 13C NMR (101 MHz,
CDCl3) δ 170.5, 170.4, 165.7, 158.5, 141.2, 134.7, 133.1, 128.9, 128.6,
128.1, 127.8, 126.9, 116.0, 68.3, 65.2, 52.9, 32.4, 11.7, 10.9; HRMS
(ESI) calcd for C23H23N2O4S (M + H
+) 423.1373, found 423.1381.
Step 2: The title compound 33 was prepared as described for 9
using methyl ester 33a (30 mg, 71 μmol) and LiI (4 equiv) and
obtained after ﬂash chromatography (EtOAc/PE, 1:1 [2% AcOH])
and subsequent freeze-drying as a white amorphous powder (18 mg,
61% yield): Rf = 0.14 (EtOAc/PE, 1:1 [2% AcOH]);
1H NMR (400
MHz, CDCl3) δ 7.56−7.34 (m, 4H), 7.33−7.20 (m, 3H), 7.19−7.08
(m, 2H), 6.12 (br s, 1H), 5.24 (app s, 1H), 3.50−3.37 (m, 2H), 2.36
(s, 3H), 2.22 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 172.7, 171.9,
165.8, 158.5, 140.5, 134.1, 133.5, 129.0, 128.8, 128.3, 127.8, 126.7,
116.0, 68.9, 65.3, 31.7, 11.7, 10.9; HRMS (ESI) calcd for
C22H21N2O4S (M + H
+) 409.1217, found 409.1228. HPLC: tR =
10.98 min, 99.9%. [α]20D +44° (c 0.3, DCM).
(2R,4R)-3-(4-(3,5-Dimethylisoxazol-4-yl)benzoyl)-2-(2-
ethynylphenyl)thiazolidine-4-carboxylic Acid (34). Step 1:
Methyl (4R)-2-(2-Ethynylphenyl)thiazolidine-4-carboxylate (7h). The
thiazolidine was prepared as described for 7a using L-cysteine methyl
ester hydrochloride (352 mg, 2.05 mmol) and 2-ethynylbenzaldehyde
(315 mg, 2.42 mmol). The crude was ﬁltered through silica (EtOAc/
PE, 1:3) and concentrated in vacuo to give the crude 7h, which was
used in the next step without further puriﬁcation.
Step 2: Methyl (2R,4R)-3-(4-(3,5-Dimethylisoxazol-4-yl)benzoyl)-2-
(2-ethynylphenyl)thiazolidine-4-carboxylate (34a). Using crude 7h (69
mg) and 4-(3,5-dimethylisoxazol-4-yl)benzoyl chloride (72 mg, 0.31
mmol), the title compound was prepared as described for 8a and
obtained after ﬂash chromatography (EtOAc/PE, 1:2) as a clear oil
(26 mg, 21% yield): Rf = 0.26 (EtOAc/PE, 1:1);
1H NMR (400 MHz,
CDCl3) δ 8.29 (d, J = 7.8 Hz, 1H), 7.48−7.43 (m, 1H), 7.40 (d, J =
7.3 Hz, 1H), 7.36−7.20 (m, 3H), 7.17−6.98 (m, 2H), 6.38 (br s, 1H),
5.21−5.04 (m, 1H), 3.90 (s, 3H), 3.46−3.39 (m, 1H), 3.31 (s, 1H),
3.36−3.22 (m, 1H), 2.34 (s, 3H), 2.20 (s, 3H); 13C NMR (101 MHz,
CDCl3) δ 170.7, 170.5, 165.7, 158.5, 144.4, 134.3, 133.1, 132.9, 129.6,
128.9, 127.9, 127.6, 126.4, 119.5, 116.1, 84.9, 80.6, 66.4, 65.7, 52.9,
31.8, 11.6, 10.8; HRMS (ESI) calcd for C25H23N2O4S (M + H
+)
447.1373, found 447.1391.
Step 3: The title compound 34 was prepared as described for 9
using methyl ester 34a (27 mg, 60 μmol) and LiI (4 equiv) and
obtained after ﬂash chromatography (EtOAc/PE, 2:1 [1% AcOH])
and subsequent freeze-drying as a brownish amorphous powder (18
mg, 70% yield): Rf = 0.16 (EtOAc/PE, 3:1 [1% AcOH]);
1H NMR
(400 MHz, CDCl3) δ 9.59 (br s, 1H), 8.03 (d, J = 6.6 Hz, 1H), 7.48−
7.36 (m, 2H), 7.36−7.20 (m, 3H), 7.17−7.03 (m, 2H), 6.43 (br s,
1H), 5.27−5.19 (m, 1H), 3.53−3.41 (m, 2H), 3.30 (s, 1H), 2.35 (s,
3H), 2.21 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 172.5, 171.8,
165.8, 158.5, 143.7, 133.8, 133.3, 133.2, 129.8, 129.1, 128.0, 127.6,
126.1, 119.5, 116.1, 85.0, 80.5, 66.9, 65.9, 31.5, 11.6, 10.8; HRMS
(ESI) calcd for C24H20N2NaO4S (M + Na
+) 455.1036, found
455.1058. HPLC: tR = 11.25 min, 99.0%. [α]
20
D +84° (c 0.2, DCM).
(2R,4R)-3-(4-(3,5-Dimethylisoxazol-4-yl)benzoyl)-2-(2-
methoxyphenyl)thiazolidine-4-carboxylic Acid (35). Step 1:
The methyl ester of the title compound (35a) was prepared as
described for 8a using 7f (69 mg, 0.27 mmol) and 4-(3,5-
dimethylisoxazol-4-yl)benzoyl chloride (71 mg, 0.30 mmol) and
obtained after ﬂash chromatography (EtOAc/PE, 1:2) as a clear oil
(91 mg, 74% yield): Rf = 0.26 (EtOAc/PE, 1:1);
1H NMR (400 MHz,
CDCl3) δ 8.18 (d, J = 6.0 Hz, 1H), 7.47−7.33 (m, 2H), 7.34−7.26
(m, 1H), 7.18−7.02 (m, 3H), 6.84 (d, J = 8.1 Hz, 1H), 6.26 (br s,
1H), 5.17−5.07 (m, 1H), 3.89 (br s, 3H), 3.73 (br s, 3H), 3.44−3.32
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(m, 1H), 3.29−3.18 (m, 1H), 2.35 (s, 3H), 2.21 (s, 3H); 13C NMR
(101 MHz, CDCl3) δ 170.6, 170.5, 165.5, 158.3, 155.2, 134.3, 132.9,
130.5, 129.2, 128.6, 127.8, 126.9, 120.9, 115.9, 110.6, 65.6, 63.1, 55.5,
52.7, 31.5, 11.6, 10.7; HRMS (ESI) calcd for C24H25N2O5S (M + H
+)
453.1479, found 453.1459.
Step 2: The title compound 35 was prepared as described for 9
using methyl ester 35a (91 mg, 0.20 mmol) and LiI (4 equiv) and
obtained after ﬂash chromatography (EtOAc/PE, 3:1 [1% AcOH])
and subsequent freeze-drying as a white amorphous powder (41 mg,
46% yield): Rf = 0.12 (EtOAc/PE, 3:1 [1% AcOH]);
1H NMR (400
MHz, DMSO-d6) δ 13.28 (br s, 1H), 8.11 (d, J = 4.8 Hz, 1H), 7.69−
7.39 (m, 1H), 7.36−7.16 (m, 4H), 7.08−6.87 (m, 2H), 6.18 (br s,
1H), 4.98−4.88 (m, 1H), 3.91−3.73 (m, 1H), 3.62 (s, 3H), 3.33−
3.05 (m, 1H), 2.36 (s, 3H), 2.18 (s, 3H); 13C NMR (101 MHz,
DMSO-d6) δ 170.9, 169.3, 165.5, 157.9, 155.0, 134.5, 131.7, 129.8,
128.9, 128.3, 126.9, 126.6, 120.3, 115.2, 110.8, 64.9, 61.7, 55.5, 31.3,
11.2, 10.3; HRMS (ESI) calcd for C23H23N2O5S (M + H
+) 439.1322,
found 439.1318. HPLC: tR = 11.11 min, 96.4%. [α]
20
D +89° (c 1.0,
MeOH).
(2R,4R)-3-(4-(3,5-Dimethylisoxazol-4-yl)benzoyl)-2-(pyridin-
2-yl)thiazolidine-4-carboxylic Acid (36). Step 1: The methyl ester
of the title compound (36a) was prepared as described for 8a using
7e (70.0 mg, 0.31 mmol) and 4-(3,5-dimethylisoxazol-4-yl)benzoyl
chloride (77 mg, 0.33 mmol) and obtained after ﬂash chromatography
(EtOAc/PE, 2:1) as a brownish viscous oil (95 mg, 73% yield): Rf =
0.21 (DCM [4% MeOH]); 1H NMR (400 MHz, CDCl3) δ 8.55−
8.37 (m, 1H), 8.16−8.00 (m, 1H), 7.83−7.64 (m, 1H), 7.57−6.74
(m, 5H), 6.41* (br s, 1H1), 6.07 (app m, 1H1), 5.63−5.52* (m, 1H2),
5.35−4.94 (m, 1H2), 3.82 (br s, 3H3), 3.64* (s, 3H3), 3.52−3.16 (m,
2H), 2.31 (s, 3H), 2.17 (s, 3H); 13C NMR (101 MHz, CDCl3) δ
170.6, 170.4, 165.6, 158.3, 149.6, 149.4, 137.1, 134.3, 133.1, 128.9,
127.6, 122.7, 120.6, 115.8, 69.4, 65.0, 52.9, 52.8, 31.8, 11.6, 10.7;
HRMS (ESI) calcd for C22H22N3O4S (M + H
+) 424.1326, found
424.1317.
Step 2: The title compound 36 was prepared as described for 9
using methyl ester 36a (51 mg, 0.12 mmol) and LiI (4 equiv) and
obtained after ﬂash chromatography (EtOAc [5% AcOH]) and
subsequent freeze-drying as a brownish amorphous powder (32 mg,
65% yield): Rf = 0.15 (EtOAc [5% AcOH]);
1H NMR (400 MHz,
MeOH-d4) δ 8.61−8.30 (m, 2H), 7.99−7.68 (m, 2H), 7.46−7.11 (m,
4H), 6.54* (s, 1H), 6.11 (br s, 1H), 5.08 (app s, 1H), 4.86* (app s,
1H), 3.66−3.35 (m, 2H), 2.46−2.33 (m, 3H), 2.29−2.14 (m, 3H);
13C NMR (101 MHz, MeOH-d4) δ 176.0, 172.4, 167.4, 161.7, 160.8,
159.8, 149.2, 148.4, 139.7, 137.0, 136.5, 133.8, 130.2, 128.9, 128.4,
124.4, 123.6, 117.2, 70.3, 69.1, 36.5, 33.5, 11.4, 10.6; HRMS (ESI)
calcd for C21H20N3O4S (M + H
+) 410.1169, found 410.1153. HPLC:
tR = 8.86 min, 97.9%. [α]
20
D +116° (c 0.5, DCM).
Synthesis of (2S,5R)-5-(2-Chlorophenyl)-1-(4-(3,5-dimethyl-
isoxazol-4-yl)benzoyl)pyrrolidine-2-carboxylic Acid (37). Step
1: Methyl (2S,5R)-5-(2-Chlorophenyl)-1-(4-(3,5-dimethylisoxazol-4-yl)-
benzoyl)pyrrolidine-2-carboxylate (37a). In a predried vial, to a
suspension of 4-(3,5-dimethylisoxazol-4-yl)benzoic acid (24 mg,
0.11 mmol; see the Supporting Information) and BTFFH (40 mg,
0.13 mmol) in dry DCM (110 μL) under argon was added DIPEA
(65 μL, 0.38 mmol), and the reaction was stirred for 2 h at rt. To the
in situ generated acid ﬂuoride was added 6 (20 mg, 83 μmol)
dissolved in dry DCM (100 μL). The vial was sealed, and the reaction
was heated to 80 °C and stirred overnight. The reaction mixture was
cooled to rt, water was added, the aqueous phase was extracted with
EtOAc (×5), and the combined organic phases were washed with
brine, dried over Na2SO4, and concentrated in vacuo to obtain 37
after ﬂash chromatography (EtOAc/PE, 1:2) as a clear viscous oil (32
mg, 86%): Rf = 0.14 (EtOAc/PE, 1:2);
1H NMR (400 MHz, CDCl3)
δ 8.32 (d, J = 7.7 Hz, 1H), 8.16−8.08 (m, 1H)*, 7.65−7.54 (m,
2H)*, 7.34−7.24 (m, 3H), 7.19−7.09 (m, 2H), 7.02 (d, J = 7.9 Hz,
2H), 5.69−5.57 (m, 1H)*, 5.41−5.31 (m, 1H), 4.81 (t, J = 7.2 Hz,
1H), 4.58−4.50 (m, 1H)*, 3.89 (s, 3H), 3.71 (s, 3H)*, 2.47−2.35
(m, 2H), 2.32 (s, 3H), 2.18 (s, 3H), 2.17−2.09 (m, 1H), 2.03−1.95
(m, 1H); 13C NMR (101 MHz, CDCl3) δ 172.9, 170.7, 165.6, 158.6,
140.4, 135.0, 132.2, 131.7, 129.2, 128.7, 128.6, 127.6, 127.3, 116.2,
61.6, 61.2, 52.5, 34.4, 27.6, 11.5, 10.7; HRMS (ESI) calcd for
C24H24ClN2O4 (M + H
+), 439.1419; found, 439.1420.
Step 2: (2S,5R)-5-(2-Chlorophenyl)-1-(4-(3,5-dimethylisoxazol-4-yl)-
benzoyl)pyrrolidine-2-carboxylic Acid (37). Ester 37a (16 mg, 37 μmol)
was dissolved in freshly distilled THF (0.4 mL), LiOHaq (0.12 mL, 0.6
M) was added, and the reaction was run at rt until full conversion of
starting material as indicated by HPLC. The reaction mixture was
quenched with HCl (1 M) until pH 2, diluted with water, extracted
with EtOAc (×5), and the organic phases were washed with brine,
dried over Na2SO4, and concentrated in vacuo to give the title
compound 37 as a cloudy viscous oil (15 mg, 93% yield): Rf = 0.23
(EtOAc/PE, 1:2 [2% AcOH]); 1H NMR (400 MHz, CDCl3) δ 7.73−
7.59 (m, 1H), 7.33−7.21 (m, 3H), 7.17−7.03 (m, 4H), 5.43 (t, J =
6.2 Hz, 1H), 4.97 (t, J = 6.5 Hz, 1H), 2.53−2.25 (m, 3H), 2.32 (s,
3H), 2.19 (s, 3H), 2.04−1.97 (m, 1H); 13C NMR (101 MHz, CDCl3)
δ 172.9, 172.8, 165.7, 158.6, 139.5, 134.0, 132.9, 131.8, 129.4, 128.9,
128.1, 127.9, 127.3, 116.1, 62.6, 62.3, 34.2, 26.6, 11.6, 10.7; HRMS
(ESI) calcd for C23H21ClN2NaO4 (M + Na
+) 447.1082, found
447.1066. HPLC: tR = 11.32 min, 99.8%. [α]
20
D −33° (c 0.4, DCM).
Crystallography. Data for 14 were collected at 100(1) K on a
Synergy, Dualﬂex, AtlasS2 diﬀractometer using Cu Kα radiation (λ =
1.541 84 Å) and the CrysAlis PRO 1.171.39.12b suite.50 Using
SHELXLE,51 the structure was solved by dual space methods
(SHELXT52) and reﬁned on F2 using all the reﬂections (SHELXL-
201653). All the non-hydrogen atoms were reﬁned using anisotropic
atomic displacement parameters. Hydrogen atoms were inserted at
calculated positions using a riding model except for the H1 of the
carboxylate group, which was located in the diﬀerence map and its
coordinates were reﬁned. The absolute conﬁguration was unambig-
uously established from the crystallographic data. Parameters for data
collection and reﬁnement are summarized in Table S1.
Molecular Modeling. A homology model of hFFA2 in complex
with 1 was obtained as described previously.32 The model was based
on a crystal structure of hFFA1 (PDB code 4PHU).54 As 31 fully
displaces [3H]-1 at increasing concentrations in a radioligand binding
assay (Table 4), the compound was docked into the binding site
deﬁned by 1. Prior to docking, 31 was prepared (LigPrep, version 2.7,
Schrödinger, LLC) using the OPLS-2005 force ﬁeld.55 Ionization
states were generated using Epik at pH 7.0 ± 2.0 (Epik, version 2.5,
Schrödinger, LLC). Induced-ﬁt docking was performed using the IFD
2006 protocol (Glide version 5.9, Schrödinger, LLC; Prime version
3.2, Schrödinger, LLC). Ligand conformational sampling was
executed using default settings; initial Glide docking was performed
using standard settings; the maximum number of poses of 31 was
restricted to 20. Redocking was executed for 31-hFFA2 complexes
within 30 kcal/mol of the lowest energy ligand−protein complex.
Residues were reﬁned within 5 Å of bound 31.
In Vitro Assays. β-Arrestin-2 Interaction Assay. HEK293T
cells were maintained in Dulbecco’s modiﬁcation of Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum, 2 mM L-
glutamine, and 1× penicillin/streptomycin mixture (Sigma) at 37 °C
and 5% CO2. Cells were grown to 60% density and co-transfected at a
4:1 ratio with plasmids encoding an eYFP-tagged form of the receptor
construct of interest and a β-arrestin-2 fused to Renilla luciferase using
a polyethyleneimine-based transfection protocol.56,57 Cells were
transferred into white 96-well plates at 24 h post-transfection and
incubated for 24 h at 37 °C. Immediately prior to conducting the
assay, cells were washed, and the culture medium was replaced with
Hanks’ balanced salt solution. To quantify β-arrestin-2 recruitment to
the receptor induced by FFA2 agonists, the Renilla luciferase substrate
coelenterazine h (Nanolight Tech, Pinetop, CA) was added to a ﬁnal
concentration of 2.5 μM, and cells were incubated for 5 min at 37 °C.
Next, varying concentrations of agonist were added, and cells were
incubated for an additional 10 min at 37 °C. BRET resulting from
receptor-β-arrestin-2 interaction was assessed by measuring the ratio
of luminescence at 535 and 475 nm using a PHERAstar FS plate
reader ﬁtted with the BRET1 optic module (BMG Labtech,
Aylesbury, U.K.). pEC50 values were determined with at least three
independent replicates.
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cAMP Assay. All cAMP experiments were performed using Flp-In
T-REx 293 cells modiﬁed to express receptors of interest in an
inducible manner, which were maintained in DMEM without sodium
pyruvate supplemented with 10% fetal bovine serum, 1× penicillin/
streptomycin mixture, 5 μg/mL blasticidin, and 200 μg/mL
hygromycin B.58 Experiments were carried out using a homogeneous
time-resolved FRET-based detection kit (Cis-Bio Bioassays, Codolet,
France) in accordance with the manufacturer’s protocol. Cells were
plated at 2000 cells/well in low-volume white 384-well plates. The
ability of compounds to inhibit 1 μM forskolin-induced cAMP
production was quantiﬁed following a 30 min incubation of agonist
compounds with cells, which were induced to express receptors of
interest by a 16 h treatment with 100 ng/mL doxycycline. pEC50
values were determined with at least three independent replicates.
Radioligand Binding Assay. Radioligand competition binding
experiments were performed as established previously.41 The
radioligand [3H]-1 at approximately Kd concentration was incubated
with varying concentrations of unlabeled compounds and 5 μg of
puriﬁed membranes isolated from Flp-In T-REx cells induced to
express the receptor construct of interest. Nonspeciﬁc binding of the
radioligand was determined in the presence of 10 μM CATPB.30 After
a 2 h incubation at 25 °C, bound [3H]-1 and free [3H]-1 were
separated by rapid vacuum ﬁltration and radioactivity was quantiﬁed
by liquid scintillation spectrometry. To determine the aﬃnity of
unlabeled ligands in terms of Ki values, competition binding curves
were ﬁt to an inverse three-parameter sigmoidal one-site Ki value ﬁt
with radioligand aﬃnity and concentration as constraints. Ki values
were determined with n = 6 independent experiments for 31 and with
n = 3 for all other compounds.
Isolation of Human Neutrophils and Migration Assay.
Neutrophils were isolated from human whole blood as described
previously.59 After isolation, neutrophils were immediately resus-
pended in RPMI 1640 containing 0.5% fatty acid-free bovine serum
albumin. Test compounds were prepared at the indicated
concentrations in the same buﬀer and added at the bottom of a 96-
well plate (Sigma-Aldrich). Inserts were then mounted to the plate,
and neutrophils were added (3000 cells/μL). Cells were incubated at
37 °C for 1.5 h, and migrated cells were then collected and ATP
content was assessed using ATPlite luminescence assay system
(PerkinElmer) according to the manufacturer’s instructions. Each
experiment was performed with n = 4−6 independent replicates.
Derivation of Primary Mouse Adipocytes and Lipolysis
Assay. Epididymal fat was collected from male mice, and isolation of
preadipocytes was obtained as described previously.59 Animals were
cared for in accordance with national guidelines on animal
experimentation. Preadipocytes were subsequently diﬀerentiated in
DMEM medium (DMEM, 10% fetal bovine serum, 4 mM glutamine,
10 mM HEPES, 10 μg/mL insulin, 25 μg/mL sodium ascorbate, 10
μM rosiglitazone) for 8 days. After this, mature adipocytes were
challenged with test compounds and glycerol production was
quantiﬁed as previously reported.59 Each experiment was performed
with n = 3−4 independent replicates.
Chemical Stability. A 10 mM stock solution of 31 in DMSO was
diluted in phosphate buﬀer (10 mM, pH = 7.4) obtaining 1.2 mL of
50 μM compound solution in phosphate buﬀer. The sample was
shaken (650 rpm) at 37 °C, and samples were taken out at diﬀerent
time intervals during the 3-week experiment. The study was
performed in duplicate, each parallel and with double injection. The
stability was calculated based on peak area of the 0 point sample.
Stability in Simulated Gastric and Intestinal Fluids. FaSSIF
and FaSSGF were prepared in accordance with the manufacturer’s
procedure. A 50 μM solution of 31 was prepared from FaSSIF/
FaSSGF and a 10 mM stock solution of 31 in DMSO, and the
samples were incubated in a thermomixer (37 °C, 650 rpm) for 0 and
120 min. Afterward, the samples were quenched with acetonitrile
(+0.5% HCOOH), centrifuged for 10 min at 10 000 rpm and the
supernatant was analyzed by HPLC. The stability was calculated
based on peak area of the 0 point sample. The study was performed in
duplicate. Average values are reported.
Microsomal Stability. Microsomal stability was studied in mouse
liver microsomes (0.5 mg/mL) at a ﬁnal test compound
concentration of 1 μM, essentially as previously described.60 In
brief, prewarmed (37 °C) 0.1 M PBS7.4 was added to 10 mM NADPH
in PBS and test compound 31 (1 mM in DMSO). The samples were
incubated for 5 min at 37 °C before addition of newly thawn
microsomes. The samples were mixed by gentle vortexing and
incubated for 1 h at 37 °C, 300 rpm in a thermomixer. Samples were
quenched by addition of ice-cold MeOH/MeCN (1:1) and
centrifuged for 5 min at 10 000g. The supernantant was transferred
to HPLC vials and stored in the freezer until analysis by HPLC. The
metabolic stability was calculated based on the 0 min sample. The
experiment was performed in triplicate.
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